<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="2.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">NCP</journal-id>
<journal-id journal-id-type="hwp">spncp</journal-id>
<journal-id journal-id-type="nlm-ta">Nutr Clin Pract</journal-id>
<journal-title>Nutrition in Clinical Practice</journal-title>
<issn pub-type="ppub">0884-5336</issn>
<issn pub-type="epub">1941-2452</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0884533611434116</article-id>
<article-id pub-id-type="publisher-id">10.1177_0884533611434116</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Invited Reviews</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Selenium Supplementation in the Critically Ill</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes" xlink:type="simple">
<name name-style="western"><surname>Hardy</surname><given-names>Gil</given-names></name>
<degrees>PhD, FRSC</degrees>
<xref ref-type="aff" rid="aff1-0884533611434116">1</xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western"><surname>Hardy</surname><given-names>Ines</given-names></name>
<degrees>BPharm, MRPharmS</degrees>
<xref ref-type="aff" rid="aff2-0884533611434116">2</xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western"><surname>Manzanares</surname><given-names>William</given-names></name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="aff3-0884533611434116">3</xref>
</contrib>
</contrib-group>
<aff id="aff1-0884533611434116"><label>1</label>Faculty of Medical and Health Sciences</aff>
<aff id="aff2-0884533611434116"><label>2</label>School of Pharmacy, University of Auckland, Auckland, New Zealand</aff>
<aff id="aff3-0884533611434116"><label>3</label>Department of Critical Care, University Hospital, Faculty of Medicine, Universidad de la República (UDELAR), Montevideo, Uruguay</aff>
<author-notes>
<corresp id="corresp1-0884533611434116">Gil Hardy, PhD, FRSC, Professor of Pharmaceutical Nutrition, Faculty of Medical and Health Sciences, University of Auckland, Private Bag 92019, Auckland, New Zealand; e-mail: <email xlink:type="simple">g.hardy@auckland.ac.nz</email>.</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>2</month>
<year>2012</year>
</pub-date>
<volume>27</volume>
<issue>1</issue>
  <issue-title>Micronutrients</issue-title>
<fpage>21</fpage>
<lpage>33</lpage>
<history>
<date date-type="received">
<day>4</day>
<month>9</month>
<year>2011</year>
</date>
<date date-type="accepted">
<day>5</day>
<month>12</month>
<year>2011</year>
</date>
</history>
<permissions>
<copyright-statement>© 2012 The American Society for Parenteral and Enteral Nutrition</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="society">The American Society for Parenteral and Enteral Nutrition</copyright-holder>
</permissions>
<abstract>
<p>Selenium (Se) is an essential trace element with antioxidant, immunological, and anti-inflammatory properties, which are attributed to its presence in selenoproteins, as the 21st amino acid selenocysteine. These selenoenzymes are involved in redox signaling, antioxidant defense, thyroid hormone metabolism, and immune responses. Dietary intakes differ considerably between geographical regions, due to variability of the Se food content, leading to differences in dietary reference intakes and toxicity cautions. Critical illness with systemic inflammatory response syndrome (SIRS) is characterized by Se depletion with high morbidity and mortality. Se status correlates well with clinical outcome in SIRS and may be useful as an early predictor of survival. Several investigators have evaluated the benefits of Se supplementation for the critically ill, either as monotherapy or in an antioxidant micronutrient combination. Pharmaconutrition, with high-dose Se (from 500–1600 µg/d) involving an initial loading bolus, followed by continuous infusion, appears to be safe and efficacious, with evidence that it can improve clinical outcome by reducing illness severity, infectious complications, and decreasing mortality in the intensive care unit (ICU). We now have a clearer understanding of the pharmacokinetics of the initial and transient pro-oxidant effect of an intravenous bolus of selenite and the antioxidant effect of continuous infusion. Better biomarkers to ascertain optimum Se requirements for individual patients are now needed, and clinical practice guidelines need improvement. Nevertheless, sufficient evidence is available to consider initiating high-dose intravenous Se therapy routinely in critically ill SIRS patients, immediately on admission to the ICU.</p>
</abstract>
<kwd-group>
<kwd>selenium</kwd>
<kwd>critically ill</kwd>
<kwd>antioxidants</kwd>
<kwd>systemic inflammation</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<p>Selenium (Se) was first discovered by the Swedish chemist Jöns Jacob Berzelius in 1817 and named after the Greek word <italic>Selene</italic>, meaning the moon.<sup><xref ref-type="bibr" rid="bibr1-0884533611434116">1</xref></sup> Since then, it has been recognized as an essential micronutrient with antioxidant, immunological, and anti-inflammatory properties for animals and human health.<sup><xref ref-type="bibr" rid="bibr2-0884533611434116">2</xref>-<xref ref-type="bibr" rid="bibr7-0884533611434116">7</xref></sup> Se has an atomic weight of 78.96 and can exist in organic molecules (as Se<sup>II</sup>) and inorganic salts such as selenate (Se<sup>VI</sup>) or selenite (Se<sup>IV</sup>). The principal dietary sources of Se are bread, cereals, dairy, eggs, fish, meat, and nuts. Dietary intake varies around the world and largely depends on whether Se-rich or Se-poor crops are cultivated and fed to animals and their geographical location.<sup><xref ref-type="bibr" rid="bibr8-0884533611434116">8</xref>,<xref ref-type="bibr" rid="bibr9-0884533611434116">9</xref></sup> Soil concentrations average around 0.4 mg/kg, but up to 1200 mg/kg are found in some seleniferous soils in China, Russia, and some North and South American states, which can lead to chronic toxic dietary intakes by residents of these areas.<sup><xref ref-type="bibr" rid="bibr10-0884533611434116">10</xref></sup> In most of North America and Japan, intakes can be high (~100–200 µg/d); in Australia, New Zealand, and the majority of European countries, intake is only marginally adequate (30–90 µg/d); but in some Eastern European countries and certain regions of China, intakes have been low (7–30 µg/d).<sup><xref ref-type="bibr" rid="bibr11-0884533611434116">11</xref>,<xref ref-type="bibr" rid="bibr12-0884533611434116">12</xref></sup></p>
<p>Evidence suggests that Se status affects both the cell-mediated and humoral aspects of immune function, which are linked to inflammatory processes involving the production of reactive oxygen species (ROS) and redox control processes. ROS production increases expression of proinflammatory cytokines through upregulation of nuclear factor–kappa B (NF-κB) activity. Lymphocytes, macrophages, and especially neutrophils require ROS and proinflammatory molecules for activation, differentiation, and phagocytosis. Depressed Se levels are associated with fewer natural killer cells.<sup><xref ref-type="bibr" rid="bibr13-0884533611434116">13</xref>,<xref ref-type="bibr" rid="bibr14-0884533611434116">14</xref></sup> On the other hand, when incorporated into the various selenoenzymes, Se acts as a crucial antioxidant influencing the inflammatory signaling pathways that modulate ROS by inhibiting activation of the NF-κB cascade and thus suppressing the production of interleukins and tumor necrosis factor–α (TNF-α).<sup><xref ref-type="bibr" rid="bibr15-0884533611434116">15</xref></sup> Se deficiency lowers antioxidant activity and thereby impairs free radical neutralization.<sup><xref ref-type="bibr" rid="bibr16-0884533611434116">16</xref></sup> Consequently, Se is arguably one of the cornerstones of the body’s antioxidant defense systems in acute critical illness.</p>
<p>Inflammatory disorders exhibiting low Se include pancreatitis, hepatitis, inflammatory bowel disease (IBD), and the systemic inflammatory response syndrome (SIRS), which generally involves oxidative stress with antioxidant depletion.<sup><xref ref-type="bibr" rid="bibr16-0884533611434116">16</xref>,<xref ref-type="bibr" rid="bibr17-0884533611434116">17</xref></sup> Severe sepsis is also characterized by an increase in ROS and low endogenous antioxidative capacity. Many severely septic patients exhibit profound Se depletion that correlates with increased mortality and morbidity.<sup><xref ref-type="bibr" rid="bibr18-0884533611434116">18</xref></sup> Thus, repletion of Se status should be able to reduce illness severity, improve clinical outcome, reduce infectious complications, and decrease mortality.<sup><xref ref-type="bibr" rid="bibr19-0884533611434116">19</xref>,<xref ref-type="bibr" rid="bibr20-0884533611434116">20</xref></sup></p>
<p>In the past two decades, several clinical trials have evaluated the role of inorganic seleno-compounds (sodium selenite or selenious acid) as part of an antioxidant strategy for critically ill SIRS patients.<sup><xref ref-type="bibr" rid="bibr17-0884533611434116">17</xref>-<xref ref-type="bibr" rid="bibr20-0884533611434116">20</xref></sup> The outcomes have been mixed, partly because the micronutrient has been studied not only as a single antioxidant (pharmaconutrient) but frequently in combination with other trace elements and vitamins in enteral or parenteral antioxidant cocktails. Recent critical care guidelines for nutrition support recommend a combination of antioxidant vitamins and trace elements (TE) (specifically including Se) for all critically ill patients requiring enteral nutrition (EN) or parenteral nutrition (PN).<sup><xref ref-type="bibr" rid="bibr21-0884533611434116">21</xref>,<xref ref-type="bibr" rid="bibr22-0884533611434116">22</xref></sup> Defining the Se requirements for “standard” EN or PN is difficult, and predicting the “enhanced” requirements of the critically ill is even more complex. However, the consensus view is that inducing a beneficial antioxidant and/or anti-inflammatory response in the critically ill necessitates a much higher “pharmaconutritional” dose than the “normal” requirement for restoration of nutrient deficiency by standard EN or PN. This therapeutic approach has resulted in some positive outcomes, with current evidence suggesting that parenteral Se therapy, at doses higher than 500 µg/d, is associated with a trend toward decreased morbidity and mortality.<sup><xref ref-type="bibr" rid="bibr16-0884533611434116">16</xref></sup> The most recent suggested posologies for enteral and parenteral Se supplementation are listed in <xref ref-type="table" rid="table1-0884533611434116">Tables 1</xref> and<xref ref-type="table" rid="table2-0884533611434116">2</xref>,<sup><xref ref-type="bibr" rid="bibr22-0884533611434116">22</xref>-<xref ref-type="bibr" rid="bibr26-0884533611434116">26</xref></sup> but the optimal dose and the best mode of administration for critically ill SIRS patients have not been clearly defined.</p>
<table-wrap id="table1-0884533611434116" position="float">
<label>Table 1.</label>
<caption>
<p>Suggested Posology for Enteral Selenium (Se) and Oral Safety Levels<sup><xref ref-type="bibr" rid="bibr23-0884533611434116">23</xref>-<xref ref-type="bibr" rid="bibr25-0884533611434116">25</xref>,<xref ref-type="bibr" rid="bibr80-0884533611434116">80</xref></sup></p>
</caption>
<graphic alt-version="no" alternate-form-of="table1-0884533611434116" position="float" xlink:href="10.1177_0884533611434116-table1.tif" xlink:type="simple"/>
<table>
<colgroup span="1">
<col align="left" span="1"/>
<col align="center" span="1"/>
</colgroup>
<thead>
<tr>
<th align="center" colspan="1" rowspan="1">Reference Source</th>
<th align="center" colspan="1" rowspan="1">Suggested Se Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="1" rowspan="1">DRI</td>
<td colspan="1" rowspan="1">55–70 µg/d</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Routine EN</td>
<td colspan="1" rowspan="1">70–112 µg/1500 kcal</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Critical care EN</td>
<td colspan="1" rowspan="1">77–100 µg/L</td>
</tr>
<tr>
<td colspan="1" rowspan="1">EU directive (EN)</td>
<td colspan="1" rowspan="1">50–200 µg/d</td>
</tr>
<tr>
<td colspan="1" rowspan="1">TUIL</td>
<td colspan="1" rowspan="1">300 µg/d</td>
</tr>
<tr>
<td colspan="1" rowspan="1">LOAEL</td>
<td colspan="1" rowspan="1">850 µg/d</td>
</tr>
<tr>
<td colspan="1" rowspan="1">NOAEL</td>
<td colspan="1" rowspan="1">900–1000 µg/d</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0884533611434116">
<p>DRI; Dietary Reference Intake; EN, enteral nutrition; EU, European Union; LOAEL, lowest observed adverse events level; NOAEL, no observed adverse effect level; TUIL: tolerable upper intake level.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table2-0884533611434116" position="float">
<label>Table 2.</label>
<caption>
<p>Suggested Posology for Parenteral Selenium (Se)<sup><xref ref-type="bibr" rid="bibr22-0884533611434116">22</xref>,<xref ref-type="bibr" rid="bibr26-0884533611434116">26</xref>,<xref ref-type="bibr" rid="bibr81-0884533611434116">81</xref></sup></p>
</caption>
<graphic alt-version="no" alternate-form-of="table2-0884533611434116" position="float" xlink:href="10.1177_0884533611434116-table2.tif" xlink:type="simple"/>
<table>
<colgroup span="1">
<col align="left" span="1"/>
<col align="center" span="1"/>
</colgroup>
<thead>
<tr>
<th align="center" colspan="1" rowspan="1">Reference Source</th>
<th align="center" colspan="1" rowspan="1">Suggested Se Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="1" rowspan="1">Standard PN</td>
<td colspan="1" rowspan="1"/></tr>
<tr>
<td colspan="1" rowspan="1"> A.S.P.E.N. current guideline</td>
<td colspan="1" rowspan="1">20–60 µg/d</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> A.S.P.E.N. workshop proposed</td>
<td colspan="1" rowspan="1">60–100 µg/d</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Critical care</td>
<td colspan="1" rowspan="1"/></tr>
<tr>
<td colspan="1" rowspan="1"> ESPEN</td>
<td colspan="1" rowspan="1">350–1000 µg/d</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> A.S.P.E.N. workshop proposed</td>
<td colspan="1" rowspan="1">100–400 µg/d</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn2-0884533611434116">
<p>A.S.P.E.N., American Society for Parenteral and Enteral Nutrition; ESPEN, European Society for Clinical Nutrition and Metabolism; PN, parenteral nutrition.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<sec id="section1-0884533611434116">
<title>Biochemical Functions of Selenium</title>
<p>A key metabolic function of Se has been attributed to its role in the enzymatic cofactor selenocysteine (SeC), the 21st amino acid, so far identified in more than 25 genes for selenoproteins in the human genome.<sup><xref ref-type="bibr" rid="bibr27-0884533611434116">27</xref>,<xref ref-type="bibr" rid="bibr28-0884533611434116">28</xref></sup> SeC is encoded by TGA (thymine-guanine-adenine) in DNA, and then a complex mechanism decodes the UGA (uracil-guanine-adenine) codon in mRNA to cotranslationally incorporate SeC into the growing polypeptide because there is no free pool of SeC in the cytosol.<sup><xref ref-type="bibr" rid="bibr29-0884533611434116">29</xref></sup> The many selenoproteins have numerous biological functions, especially related to redox signaling, the antioxidant defense system, thyroid hormone metabolism, and immune response. The most extensively characterized selenoenzymes are those in the glutathione peroxidase (GPx) family, consisting of 8 isoforms that catalyze the reduction of various hydroperoxides but differ in their substrate specificity<sup><xref ref-type="bibr" rid="bibr30-0884533611434116">30</xref></sup>—namely, cytosolic GPx1, gastrointestinal GPx2, plasma GPx3, and phospholipid/cholesterol hydroperoxides GPx4.<sup><xref ref-type="bibr" rid="bibr28-0884533611434116">28</xref></sup> GPx3 also acts as a functional parameter for Se status, and deficiencies have been associated with cardiovascular disease (CVD), stroke, and sepsis.<sup><xref ref-type="bibr" rid="bibr31-0884533611434116">31</xref></sup></p>
<p>Selenoprotein P (SePP), produced in the liver, is the major circulating form of Se in plasma.<sup><xref ref-type="bibr" rid="bibr32-0884533611434116">32</xref></sup> It contains up to 10 SeC per protein, indicative of a high antioxidant potential. A key characteristic of SePP is its ability to bind to the endothelium, which may be a mechanism for SePP recruitment to the site of inflammation,<sup><xref ref-type="bibr" rid="bibr33-0884533611434116">33</xref>-<xref ref-type="bibr" rid="bibr36-0884533611434116">36</xref></sup> but there remains an element of tissue specificity with respect to production and uptake that requires further investigation.<sup><xref ref-type="bibr" rid="bibr8-0884533611434116">8</xref></sup> The manner in which dietary Se is absorbed and then transported from the enterocytes via the portal system for incorporation into SePP depends on its oxidation state and whether the substrate is organic or inorganic. Conversion of dietary Se into selenoproteins occurs through a variety of metabolic pathways involving SeC and other seleno amino acids, such as selenomethionine (SeM), which are released from digested protein by catabolic processes and then conveyed by amino acid transporter systems.<sup><xref ref-type="bibr" rid="bibr37-0884533611434116">37</xref></sup></p>
<p>Se also has an important role in thyroid hormone metabolism.<sup><xref ref-type="bibr" rid="bibr38-0884533611434116">38</xref>,<xref ref-type="bibr" rid="bibr39-0884533611434116">39</xref></sup> Thioredoxin reductases (TRxR) and iodothyronine deiodinases are selenoenzymes that release hydrogen selenide (H2Se), from dietary Se, to interact with glutathione (GSH) to form selenodiglutathione (GSSeSG) in redox reactions. Thyroid metabolism can be disturbed posttraumatically, and it has been shown that low plasma Se levels in critically ill patients correlate with low T3 levels. Moreover, Se supplementation leads to an earlier normalization of plasma T3 levels compared with controls but, Se repletion has no direct effect on the activity of free and total thyroid hormones.<sup><xref ref-type="bibr" rid="bibr38-0884533611434116">38</xref></sup> Nevertheless, these studies would suggest that the main cause of low T3 levels could be decreased activity of the selenoenzyme deiodinase (5′DI), which catalyzes peripheral T4 deiodination.<sup><xref ref-type="bibr" rid="bibr39-0884533611434116">39</xref></sup></p>
</sec>
<sec id="section2-0884533611434116">
<title>Recommended Intakes of Selenium in Health and Critical Illness</title>
<p>A range of different recommendations to ensure adequate dietary intake of Se for free living healthy populations has been estimated from dietary surveys and food composition tables, all of which have inherent inaccuracies: underreporting can be up to 25%,<sup><xref ref-type="bibr" rid="bibr40-0884533611434116">40</xref></sup> and robust Se concentrations in different foods are either lacking or below detection limits at the time of analysis.</p>
<p>The World Health Organization (WHO) recommendations were established on the basis of two-thirds maximal GPx3 activity rather than full saturation. Although 30–40 µg/d may be adequate to optimize GPx3, WHO concedes that other GPx markers may require considerably more supplementation—that is, 70 µg/d is necessary for Se-deficient populations, whereas a toxic level of 900 µg/d is potentially harmful.<sup><xref ref-type="bibr" rid="bibr41-0884533611434116">41</xref>,<xref ref-type="bibr" rid="bibr42-0884533611434116">42</xref></sup> The average WHO body weight (BW) at 65 kg is based on that for developing countries but is far less than most Western countries. It may well be that BW and body mass index (BMI) are important dietary confounders not previously given sufficient attention. These data emphasize the difficulties in establishing Dietary Reference Intakes (DRIs) and point to the fact that high Se doses, potentially dangerous to a free-living healthy population, may not be toxic during short-term therapy in intensive care unit (ICU) patients with well-documented low Se status. A more personalized approach and more precise dosing regimens will be necessary in future studies.</p>
</sec>
<sec id="section3-0884533611434116">
<title>Low Selenium Status in the Critically Ill</title>
<p>SePP is the major selenoenzyme, accounting for up to 60% of Se in plasma,<sup><xref ref-type="bibr" rid="bibr8-0884533611434116">8</xref>,<xref ref-type="bibr" rid="bibr33-0884533611434116">33</xref>,<xref ref-type="bibr" rid="bibr34-0884533611434116">34</xref></sup> and has been shown to be responsive to changes in dietary intake.<sup><xref ref-type="bibr" rid="bibr32-0884533611434116">32</xref></sup> A further 30% is measurable as GPx-3 with a normal value of 0.72 ± 0.16 U/mL,<sup><xref ref-type="bibr" rid="bibr43-0884533611434116">43</xref></sup> and approximately 6%–10% is bound to albumin, with less than 1% existing as free Se.<sup><xref ref-type="bibr" rid="bibr8-0884533611434116">8</xref>,<xref ref-type="bibr" rid="bibr44-0884533611434116">44</xref>,<xref ref-type="bibr" rid="bibr45-0884533611434116">45</xref></sup></p>
<p>Se status can be assessed by determining the Se concentration of whole blood, plasma, serum, or erythrocytes. A meta-analysis of 14 Se supplementation/depletion studies confirmed that plasma or serum levels are the most commonly used and reasonably accurate biomarkers of Se status, responding to short-term changes in intake.<sup><xref ref-type="bibr" rid="bibr46-0884533611434116">46</xref></sup> Measurement is relatively easy, if trace element–free needles and collection tubes are used to avoid environmental contamination. Expression of individual selenoproteins may be a more accurate measure, as SePP responds to Se supplementation in a dose-dependant way and is more sensitive to deficiency than GPx, but it is still difficult to determine.</p>
<p>Environmental factors influence Se status in several populations. A review of 65 studies of European adult plasma Se levels published between 1995 and 2003 reported values ranging from 50–145 µg/L,<sup><xref ref-type="bibr" rid="bibr47-0884533611434116">47</xref></sup> but most fell below the mean of 78.96 µg/L (1.00 µmol/L). Our small sample of Uruguayan healthy individuals exhibited similar serum Se levels (72.8 ± 13.1 µg/L).<sup><xref ref-type="bibr" rid="bibr43-0884533611434116">43</xref></sup> Thus, there are likely to be many patient populations where Se consumption (100 µg/d) may not have been sufficient for optimal GPx or SePP activity prior to their illness, surgery, or trauma. Suboptimal or “borderline” levels may aggravate or predispose some to deficiency in critical illness, where Se requirements are greater due to oxidative stress. The elderly, for example, may be on multiple medications, some of which, such as statins, compromise TE status<sup><xref ref-type="bibr" rid="bibr48-0884533611434116">48</xref></sup> or corticosteroids that increase urinary Se losses.<sup><xref ref-type="bibr" rid="bibr49-0884533611434116">49</xref></sup> Other factors, including, smoking, alcoholism, and human immunodeficiency virus (HIV)/AIDS, can all be associated with impaired liver function tests and lower recorded Se levels.<sup><xref ref-type="bibr" rid="bibr50-0884533611434116">50</xref>-<xref ref-type="bibr" rid="bibr52-0884533611434116">52</xref></sup> Malnutrition and dehydration associated with heroin and other substances of addiction also manifest as low Se levels.<sup><xref ref-type="bibr" rid="bibr53-0884533611434116">53</xref></sup></p>
<p>During critical illness, TE availability is substantially modified.<sup><xref ref-type="bibr" rid="bibr54-0884533611434116">54</xref>-<xref ref-type="bibr" rid="bibr59-0884533611434116">59</xref></sup> SIRS is associated with redistribution of vitamins and TE from the circulating compartment to those tissues involved in protein synthesis and immune cell proliferation, which could explain the finding of an early decrease of the selenoenzymes GPx-3 and SePP in SIRS patients.<sup><xref ref-type="bibr" rid="bibr55-0884533611434116">55</xref>-<xref ref-type="bibr" rid="bibr57-0884533611434116">57</xref></sup> Like other micronutrients, Se escapes to the interstitial compartment by capillary leakage. In addition, losses through biological fluids, hemodilution, previous insufficient intake, and continuous renal replacement therapies (CRRTs) contribute to Se depletion (<xref ref-type="table" rid="table3-0884533611434116">Table 3</xref>).<sup><xref ref-type="bibr" rid="bibr60-0884533611434116">60</xref></sup> Several recent studies indicate that Se status correlates well with clinical outcome and may be useful as an early predictor of survival in the ICU. Forceville et al<sup><xref ref-type="bibr" rid="bibr17-0884533611434116">17</xref></sup> investigated 134 consecutive ICU patients and showed plasma Se levels decreased up to 40%, especially in septic shock. In addition, a Se concentration lower than 0.7 µmol/L was associated with a 4-fold increase in mortality and a 3-fold increase in new organ failure and ventilator-associated pneumonia (VAP). More recently, the same group has reported an early 70% decrease (within 48 hours of ICU admission) in SePP plasma levels in severe sepsis and septic shock, whereas GPx-3 activity remained unchanged.<sup><xref ref-type="bibr" rid="bibr61-0884533611434116">61</xref></sup> In 55 of 60 (92%) surgical patients at ICU admission, Sakr et al<sup><xref ref-type="bibr" rid="bibr62-0884533611434116">62</xref></sup> showed that plasma Se levels were lower than healthy controls (74 µg/L) and further decreased during the ICU stay for SIRS patients, as well as those with organ failure, due to severe sepsis. Nonsurvivors had lower Se plasma values than normal at ICU admission and remained so during their ICU stay.</p>
<table-wrap id="table3-0884533611434116" position="float">
<label>Table 3.</label>
<caption>
<p>Etiology of selenium (Se) Depletion in the Critically Ill</p>
</caption>
<graphic alt-version="no" alternate-form-of="table3-0884533611434116" position="float" xlink:href="10.1177_0884533611434116-table3.tif" xlink:type="simple"/>
<table>
<colgroup span="1">
<col align="left" span="1"/>
</colgroup>
<tbody>
<tr>
<td colspan="1" rowspan="1">1. Low Se status before hospitalization (alcoholics, elderly, HIV/AIDS, smokers)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">2. Cutaneous exudates (burns, wounds)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">3. High urine output</td>
</tr>
<tr>
<td colspan="1" rowspan="1">4. CRRT, dialysis</td>
</tr>
<tr>
<td colspan="1" rowspan="1">5. Diarrhea, fistulae, vomiting</td>
</tr>
<tr>
<td colspan="1" rowspan="1">6. High-volume gastric residuals</td>
</tr>
<tr>
<td colspan="1" rowspan="1">7. Open abdomen</td>
</tr>
<tr>
<td colspan="1" rowspan="1">8. Drains (abdomen and thorax)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">9. Drugs (diuretics, statins, corticosteroids)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">10. Capillary leakage (SIRS)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">11. Hemodilution due to fluid therapy</td>
</tr>
<tr>
<td colspan="1" rowspan="1">12. Insufficient Se in EN or PN regimens</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3-0884533611434116">
<p>CRRT, continuous renal replacement therapy; EN, enteral nutrition; HIV, human immunodeficiency virus; PN, parenteral nutrition; SIRS, systemic inflammatory response syndrome.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Our multidisciplinary intensive care research group<sup><xref ref-type="bibr" rid="bibr43-0884533611434116">43</xref></sup> confirmed the French findings that Se and GPX-3 are significantly decreased in SIRS and multiple-organ dysfunction syndrome (MODS) patients (<italic>P</italic> = .0001 and <italic>P</italic> = .002, respectively). In addition, univariate analysis showed that plasma Se has a relatively good predictive value for ICU mortality (<italic>P</italic> = .034), but GPx-3 does not (<italic>P</italic> = .056). This means the lower the Se level, the higher the ICU mortality. The Se cutoff value of 60 µg/L and the GPx-3 cutoff value of 0.5 U/mL have high specificity (81.2% and 93.7%, respectively) for the evaluation and prediction of MODS. Furthermore, the area under the curves (AUC) of GPx-3 and Se demonstrates that these are excellent predictors of SIRS: GPx-3 yielded the highest discriminative value, with an AUC of 0.921 (95% confidence interval [CI], 0.844–0.999). Further confirmation is provided by a recent study<sup><xref ref-type="bibr" rid="bibr63-0884533611434116">63</xref></sup> showing that Se whole-blood levels were significantly reduced during cardiopulmonary bypass surgery when compared to preoperative values (89.05 ± 12.65 vs 70.84 ± 10.46 µg/L). In addition, low Se blood levels at the end of surgery were independently associated with the postoperative occurrence of MODS (odds ratio [OR] = 0.8479; 95% CI, 0.7617–0.9440; <italic>P</italic> = .0026). On the basis of all these data, we have proposed that early assessment of Se status should be mandatory for all patients on admission to the ICU.<sup><xref ref-type="bibr" rid="bibr43-0884533611434116">43</xref></sup></p>
</sec>
<sec id="section4-0884533611434116">
<title>Seleno-Compounds in the Critically Ill: Molecular Effects and Pharmacokinetics Issues</title>
<p>In addition to the different chemical forms of Se, the mode of administration appears to influence the pharmacokinetics of Se therapy and hence may account for the conflicting results of different supplementation studies. The following options are available: single-nutrient monotherapy or in combination with other micronutrients, bolus vs continuous infusion, and bolus plus continuous infusion or incorporated with other TE into a PN regimen. Most intervention trials in the ICU have been performed using the parenteral route, and we lack comparative data between enteral and parenteral Se supplementation. Inorganic seleno-compounds (sodium selenite or selenious acid) are the most efficacious parenteral forms of Se supplementation for optimizing GPx-3 activity<sup><xref ref-type="bibr" rid="bibr44-0884533611434116">44</xref>,<xref ref-type="bibr" rid="bibr45-0884533611434116">45</xref>,<xref ref-type="bibr" rid="bibr64-0884533611434116">64</xref></sup> and have been evaluated in several clinical and animal studies. Moreover, organic Se compounds, such as selenomethionine, are not available for intravenous (i.v.) use.<sup><xref ref-type="bibr" rid="bibr59-0884533611434116">59</xref></sup></p>
<p>The optimum safe dose and method of administration remains controversial,<sup><xref ref-type="bibr" rid="bibr18-0884533611434116">18</xref></sup> but the best clinical outcomes in SIRS, with no apparent adverse effects, have been reported from very high Se doses, administered by bolus followed by continuous infusion. Selenite is postulated to have a biphasic action—initially as a pro-oxidant and then as an antioxidant and, depending on intracellular conditions such as peroxide tone and redox potential, can potentially have a toxic effect. Nevertheless, the early transient pro-oxidant effect of selenite might be a useful therapeutic strategy for some ICU patients.<sup><xref ref-type="bibr" rid="bibr44-0884533611434116">44</xref>,<xref ref-type="bibr" rid="bibr45-0884533611434116">45</xref></sup> A loading dose given as a bolus in the early phase of septic shock and SIRS could have the following effects: (a) direct reversible inhibition of NF-κB binding to DNA through a rupture of the disulfide bridging bond controlling gene expression and thus downregulating the synthesis of proinflammatory cytokines (at Se concentrations higher than 5 µmol/L),<sup><xref ref-type="bibr" rid="bibr65-0884533611434116">65</xref>-<xref ref-type="bibr" rid="bibr67-0884533611434116">67</xref></sup>
<bold>(</bold>b) induction of apoptosis and cytotoxicity in activated proinflammatory circulating cells at the microcirculation level,<sup><xref ref-type="bibr" rid="bibr68-0884533611434116">68</xref></sup> and (c) a direct virucidal and bactericidal effect.<sup><xref ref-type="bibr" rid="bibr44-0884533611434116">44</xref></sup> The antioxidant action of high doses of Se is secondary to its incorporation into SeC residues at the active site of the selenoenzymes.<sup><xref ref-type="bibr" rid="bibr44-0884533611434116">44</xref>,<xref ref-type="bibr" rid="bibr45-0884533611434116">45</xref></sup> In patients with septic shock, the combined effect of an i.v. bolus followed by continuous infusion stimulates the synthesis of SePP, thereby exerting a protective action leading to decreased endothelial dysfunction and organ failure.<sup><xref ref-type="bibr" rid="bibr61-0884533611434116">61</xref></sup></p>
<p>Our own dosing study performed in 20 critically ill SIRS patients<sup><xref ref-type="bibr" rid="bibr69-0884533611434116">69</xref></sup> compared and analyzed the pharmacokinetic profile of 2 high doses of selenite (as selenious acid). The first group received a bolus loading dose of 1200 µg (15.18 µmol) over 2 hours and thereafter 800 µg/d (10.12 µmol/d) as a continuous infusion for 10 days. The second group received a loading dose of 2000 µg (25.3 µmol) and thereafter 1600 µg/d (20.24 µmol) as a continuous infusion during the same time period. Data analysis showed that the concentration-time curves for Se overlapped and were independent of dose. However, the pharmacodynamic profile of GPx showed that optimal GPx-3 levels were achieved only with the higher dose of selenious acid (1600 µg/d Se). In both groups, GPx-3 decreased after day 7 of supplementation and was independent from the Se dose. Clinical outcomes were similar in both groups.</p>
<p>There is no doubt that urinary Se excretion is greater after bolus injection than when given by a continuous infusion over 8–24 hours in normal saline.<sup><xref ref-type="bibr" rid="bibr59-0884533611434116">59</xref>,<xref ref-type="bibr" rid="bibr62-0884533611434116">62</xref></sup> Nevertheless, the same pharmacodynamic profiles are not observed from the latter mode of administration or by incorporating the Se into a PN regimen, which is also constantly infused.<sup><xref ref-type="bibr" rid="bibr18-0884533611434116">18</xref></sup> Using a sheep model of severe peritoneal sepsis and septic shock, Wang et al<sup><xref ref-type="bibr" rid="bibr70-0884533611434116">70</xref></sup> have investigated the effects of a large Se bolus (as sodium selenite 2000 µg) into the right atrium, followed by a continuous i.v. infusion of 0.06 µg/kg/h for the remainder of the study. A second group received the same dose of sodium selenite but only by continuous infusion (4 µg/kg/h) without the initial bolus. Only bolus-injected animals, but not the continuous infusion group, reached a transient peak plasma Se concentration (7.7 ± 2.7 µmol/L, 4–14 µmol/L). In addition, interleukin-6 (IL-6) decreased significantly but only in the bolus group (<italic>P</italic> &lt; .05). These metabolic improvements were associated with a better hemodynamic status: blood pressure, cardiac index, stroke volume index, and response to fluid replacement (<italic>P</italic> &lt; .05), suggesting that in an inflammatory condition, such as severe sepsis/septic shock, the pro-oxidant effect of a large Se bolus may be pivotal to the anti-inflammatory process and hence outcome improvement.</p>
</sec>
<sec id="section5-0884533611434116">
<title>Safety of Selenium Supplementation in the Critically Ill</title>
<p>The mechanisms underlying Se toxicity are complex and not fully understood but probably involve induction of oxidative stress and replacement of a sulfur atom (S) with Se in key molecules, causing structural defects.<sup><xref ref-type="bibr" rid="bibr8-0884533611434116">8</xref></sup> Early experimental data suggest negligible respiratory excretion of Se metabolites at doses &lt;100 µg/kg, with toxic symptoms occurring only at doses &gt;1000 µg/kg.<sup><xref ref-type="bibr" rid="bibr71-0884533611434116">71</xref></sup> Levels of dietary exposure at which Se becomes toxic and selenosis develops are difficult to establish. The chemical form of Se, whether organic or inorganic; potential combinations with other dietary components; and the effect of genotype are important factors that have been extensively reviewed by Valdiglesias et al,<sup><xref ref-type="bibr" rid="bibr72-0884533611434116">72</xref></sup> who draw attention to the limitations and dangers of extrapolating results from in vitro assays to the clinical situation. Symptoms of toxic selenosis resulting from acute and long-term oral intakes of up to 38,000 µg/d have been observed in populations living in seleniferous regions.<sup><xref ref-type="bibr" rid="bibr71-0884533611434116">71</xref></sup> In the Chinese province of Hubei, where severe selenosis was reported,<sup><xref ref-type="bibr" rid="bibr73-0884533611434116">73</xref></sup> the average daily intake was 4990 µg. Likewise, crops and animal fodder in the Indian Punjab containing very high Se provided daily intakes of ~623 µg/d for men and 475 µg/d for women, compared to average levels of 65 and 52 µg/d in nonseleniferous areas of India.<sup><xref ref-type="bibr" rid="bibr10-0884533611434116">10</xref>,<xref ref-type="bibr" rid="bibr74-0884533611434116">74</xref></sup> On the other hand, the Inuit of North Greenland are known to ingest up to 5885 µg/d from whale and seal meat sources, resulting in plasma levels of 1000 µg/L with no obvious signs of toxicity.<sup><xref ref-type="bibr" rid="bibr75-0884533611434116">75</xref></sup></p>
<p>More than 25 years ago, Olson<sup><xref ref-type="bibr" rid="bibr76-0884533611434116">76</xref></sup> reviewed the toxicity of Se and suggested that the maximum safe daily selenite dose should be 0.05 mg/kg (or 3500 µg/70 kg/d human). He noted that neurotoxicity, anemia, liver dysfunction, and pancreatic changes were observed at doses ranging between 0.03 and 0.4 mg/kg/d. According to WHO, ingestion of a single high oral dose of 250 mg Se results in acute toxicity (selenosis) with nausea, vomiting, nail changes, dryness of hair, hair loss, tenderness and swelling of fingertips, fatigue, irritability, and garlicky breath.<sup><xref ref-type="bibr" rid="bibr77-0884533611434116">77</xref></sup> The minimum chronic daily oral intake (usually over several months) sufficient to cause symptoms of selenosis such as hair or nail loss, mottled teeth, skin lesions, and peripheral nerve damage in healthy individuals is about 1200 µg Se (range, 900–1900 µg Se).<sup><xref ref-type="bibr" rid="bibr78-0884533611434116">78</xref></sup> The lowest observed adverse events level (LOAEL) for clinical symptoms of selenosis is 900–1000 µg Se/d. No selenosis has been recorded in individuals with blood Se concentrations below 1000 µg/L (corresponding to an approximate daily intake of 850 µg), and this has been taken as a NOAEL (no observed adverse effect level) for clinical selenosis.<sup><xref ref-type="bibr" rid="bibr79-0884533611434116">79</xref></sup> In 2000, the Scientific Committee on Food, deliberating on the tolerable upper intake level (TUIL) of Se, established a TUIL for dietary Se of 300 µg/d in adults, including pregnant and lactating women.<sup><xref ref-type="bibr" rid="bibr80-0884533611434116">80</xref></sup> Certainly, Se levels increase in a dose-dependent manner, and a risk of toxicity exists at the highest levels of supplementation. Nevertheless, most of the published human toxicity data relate to chronic oral intakes (over months rather than weeks) and cannot necessarily be extrapolated to the situation in the ICU, where high-dose Se is not advocated for more than 2 weeks.<sup><xref ref-type="bibr" rid="bibr18-0884533611434116">18</xref></sup></p>
<p>What, then, is the optimum therapeutic but safe posology for critically ill patients? It has been suggested that parenteral Se doses &gt;400 µg/d could be harmful,<sup><xref ref-type="bibr" rid="bibr81-0884533611434116">81</xref></sup> but this seems to be based on the TUIL recommended for daily oral intake of at least 3 months and is actually less than half the WHO toxic level of 900 µg/d.<sup><xref ref-type="bibr" rid="bibr77-0884533611434116">77</xref></sup> Heyland<sup><xref ref-type="bibr" rid="bibr82-0884533611434116">82</xref></sup> in turn has suggested that doses &gt;1000 µg/d could be harmful but proposed that a dose &lt;800 µg/d (the figure currently employed in the Reducing Deaths due to Oxidative Stress [REDOXS] study) is probably inadequate and ineffective for Se-deficient ICU patients. On the other hand, Vincent and Forceville<sup><xref ref-type="bibr" rid="bibr44-0884533611434116">44</xref></sup> have proposed that any dose below the TUIL may be used in the critically ill, but doses &gt;800 µg/d need to be researched further. However, all these suggestions are speculative and not sustained by strong toxicological evidence. The extremely high oral doses producing selenosis are orders of magnitude greater than the “high” pharmaconutritional therapeutic doses employed in the ICU, where acute doses up to 1600 µg/d for 14 days have been administered, via the i.v. route, without adverse events.<sup><xref ref-type="bibr" rid="bibr19-0884533611434116">19</xref>,<xref ref-type="bibr" rid="bibr20-0884533611434116">20</xref></sup></p>
<p>Animal data suggest that early peak plasma Se and a transient pro-oxidant effect are obtained only after i.v. bolus injection.<sup><xref ref-type="bibr" rid="bibr70-0884533611434116">70</xref>,<xref ref-type="bibr" rid="bibr83-0884533611434116">83</xref>,<xref ref-type="bibr" rid="bibr84-0884533611434116">84</xref></sup> According to a review of the 12 most important Se trials up to 2004, the total dose of Se administered to critically ill patients is wide ranging: from 2500–29,000 µg (29 mg) over a supplementation period between 5 and 28 days.<sup><xref ref-type="bibr" rid="bibr85-0884533611434116">85</xref></sup> Taking into account total parenteral and enteral Se, the protocols from Germany<sup><xref ref-type="bibr" rid="bibr19-0884533611434116">19</xref></sup> and Uruguay<sup><xref ref-type="bibr" rid="bibr20-0884533611434116">20</xref>,<xref ref-type="bibr" rid="bibr69-0884533611434116">69</xref></sup> have supplemented a total Se dose ranging up to 18,000 µg (18 mg) during 10–14 days. Neither investigator teams have reported any Se-specific adverse events due to the high acute-dose Se supplementation but have demonstrated improvements in certain clinical end points (<xref ref-type="table" rid="table4-0884533611434116">Table 4</xref>).<sup><xref ref-type="bibr" rid="bibr19-0884533611434116">19</xref>,<xref ref-type="bibr" rid="bibr20-0884533611434116">20</xref></sup></p>
<table-wrap id="table4-0884533611434116" position="float">
<label>Table 4.</label>
<caption>
<p>Posology of Selenium Pharmaconutrition in the Critically Ill (Daily Dose, Total Dose, and Duration of Therapy)</p>
</caption>
<graphic alt-version="no" alternate-form-of="table4-0884533611434116" position="float" xlink:href="10.1177_0884533611434116-table4.tif" xlink:type="simple"/>
<table>
<colgroup span="1">
<col align="left" span="1"/>
<col align="left" span="1"/>
<col align="center" span="1"/>
<col align="center" span="1"/>
</colgroup>
<thead>
<tr>
<th align="left" colspan="1" rowspan="1">Study</th>
<th align="center" colspan="1" rowspan="1">Daily Dose, µg</th>
<th align="center" colspan="1" rowspan="1">Duration of Supplementation, d</th>
<th align="center" colspan="1" rowspan="1">Total Dose, µg</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="1" rowspan="1">Kuklinski et al (1995)<sup><xref ref-type="bibr" rid="bibr86-0884533611434116">86</xref></sup></td>
<td colspan="1" rowspan="1">Day 1: 1000<break/>Day 2+: 500</td>
<td colspan="1" rowspan="1">5+</td>
<td colspan="1" rowspan="1">3000+</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Zimmermann et al (1997)<sup><xref ref-type="bibr" rid="bibr87-0884533611434116">87</xref></sup></td>
<td colspan="1" rowspan="1">Day 1: 2000<break/>Days 2–14: 1000</td>
<td colspan="1" rowspan="1">14</td>
<td colspan="1" rowspan="1">15,000</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Angstwurm et al (1999)<sup><xref ref-type="bibr" rid="bibr88-0884533611434116">88</xref></sup></td>
<td colspan="1" rowspan="1">Day 1–3: 535<break/>Day 4–6: 285<break/>Day 7–9: 160</td>
<td colspan="1" rowspan="1">9</td>
<td colspan="1" rowspan="1">2940</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Angstwurm et al (2007)<sup><xref ref-type="bibr" rid="bibr19-0884533611434116">19</xref></sup></td>
<td colspan="1" rowspan="1">Day 1: 2000<break/>Days 2–14: 1000</td>
<td colspan="1" rowspan="1">14</td>
<td colspan="1" rowspan="1">15,000</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Mishra et al (2007)<sup><xref ref-type="bibr" rid="bibr100-0884533611434116">100</xref></sup></td>
<td colspan="1" rowspan="1">Days 1–3: 474<break/>Days 4–6: 316<break/>Days 7–9: 158<break/>Days 9–14: 31.6</td>
<td colspan="1" rowspan="1">14</td>
<td colspan="1" rowspan="1">3000</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Forceville et al (2007)<sup><xref ref-type="bibr" rid="bibr101-0884533611434116">101</xref></sup></td>
<td colspan="1" rowspan="1">Day 1: 4000<break/>Days 2–10: 1000</td>
<td colspan="1" rowspan="1">10</td>
<td colspan="1" rowspan="1">13,000</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Heyland et al (2007)<sup><xref ref-type="bibr" rid="bibr96-0884533611434116">96</xref></sup></td>
<td colspan="1" rowspan="1">Enteral: 300<break/>Parenteral: 500</td>
<td colspan="1" rowspan="1">28</td>
<td colspan="1" rowspan="1">22,400</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Soguel et al (2008)<sup><xref ref-type="bibr" rid="bibr93-0884533611434116">93</xref></sup></td>
<td colspan="1" rowspan="1">Enteral: 300<break/>Parenteral: 485.5</td>
<td colspan="1" rowspan="1">10</td>
<td colspan="1" rowspan="1">7855</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Manzanares et al (2010)<sup><xref ref-type="bibr" rid="bibr69-0884533611434116">69</xref></sup></td>
<td colspan="1" rowspan="1">Day 1: 2000<break/>Days 2–10: 800</td>
<td colspan="1" rowspan="1">10</td>
<td colspan="1" rowspan="1">9200</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Andrews et al (2011)<sup><xref ref-type="bibr" rid="bibr99-0884533611434116">99</xref></sup></td>
<td colspan="1" rowspan="1">500</td>
<td colspan="1" rowspan="1">7</td>
<td colspan="1" rowspan="1">3500</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Valenta et al (2011)<sup><xref ref-type="bibr" rid="bibr102-0884533611434116">102</xref></sup></td>
<td colspan="1" rowspan="1">Day 1: 1000<break/>Days 2–14: 500</td>
<td colspan="1" rowspan="1">14</td>
<td colspan="1" rowspan="1">8000</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Manzanares et al (2011)<sup><xref ref-type="bibr" rid="bibr20-0884533611434116">20</xref></sup></td>
<td colspan="1" rowspan="1">Day 1: 3600<break/>Days 2–10: 1600</td>
<td colspan="1" rowspan="1">10</td>
<td colspan="1" rowspan="1">18,000</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>Given that the i.v. route seems to be the most efficacious and cost-effective way to deliver sufficient Se to create a pharmacological response that will improve clinical outcomes, we need to be sure that safety remains paramount. To achieve this aim, perhaps further refinement in posology, based on body weight or BMI, is necessary. In the Selenium in Intensive Care (SIC) study,<sup><xref ref-type="bibr" rid="bibr19-0884533611434116">19</xref></sup> the mean BMI was 27.1 ± 6.8 kg/m<sup>2</sup>, but 10% of patients had low BMI (&lt;20 kg/m<sup>2</sup>) and 7.5% had a high BMI (&gt;40 kg/m<sup>2</sup>). Each patient received a fixed Se dose of approximately 1071 µg/d, which equates to a mean of 14 µg/kg/d, but those with the lowest BMI would have received approximately 19 µg/kg/d and those with high BMI only 11 µg/kg/d, a significant 67% difference that might have affected outcome. Similarly, in our pilot supplementation study,<sup><xref ref-type="bibr" rid="bibr20-0884533611434116">20</xref></sup> the mean BMI was 25 ± 7.0 kg/m<sup>2</sup>. Individual patients in the Se intervention group received a mean daily infusion of 22 µg/kg/d Se from the combination of bolus plus continuous infusion, but the range of BMI and therefore the actual dosage were similar to the SIC study and could have varied by as much as 70% from one patient to another. These are merely speculations at this stage, but perhaps in future studies, a daily dose based on BMI and/or other anthropometric assessments could refine pharmaconutrition therapy and further improve outcomes.</p>
</sec>
<sec id="section6-0884533611434116">
<title>Parenteral Selenium Supplementation in the Critically Ill</title>
<p>No expert DRI panel has to date issued any advice on the risks of poor Se status for specific populations such as smokers, patients with HIV/AIDS, alcoholics, or those on PN or EN, all of which may be more prevalent in the critically ill. The dosage of Se for such patients probably needs to be very different. In the early 1990s, some seminal research from Germany and Switzerland investigated different doses of parenteral Se as sodium selenite in ICU patients. Kuklinski et al<sup><xref ref-type="bibr" rid="bibr86-0884533611434116">86</xref></sup> showed that a sodium selenite loading dose of 200 µg and then 800 µg infused over the next 24 hours, followed by a continuous infusion of 500 µg from day 2 after ICU admission, was associated with a significant improvement in the prognosis of patients with severe acute pancreatitis. The same researchers<sup><xref ref-type="bibr" rid="bibr87-0884533611434116">87</xref></sup> then administered a higher dose of 1000 µg sodium selenite as a bolus injection for 30 minutes on the first day followed by continuous infusion of 1000 µg/d for 14 days to ICU patients after surgery or trauma. This posology significantly improved multiorgan function scores with a 2.6-fold reduction in mortality. In a nonblinded, randomized, placebo-controlled trial in SIRS patients with an Acute Physiology and Chronic Health Evaluation II (APACHE II) score &gt;15, Angstwurm et al<sup><xref ref-type="bibr" rid="bibr88-0884533611434116">88</xref></sup> followed this novel protocol, involving an initial i.v. bolus followed by a stepwise reduction in dosage of sodium selenite (535 µg from days 1–3, 285 µg from days 4–6, and 160 µg from days 7–9) as continuous infusions and thereafter 35 µg sodium selenite in the PN. Se supplementation reduced the severity index and the need for hemodialysis, but the reduction in mortality (52% to 33.5%) did not reach significance (<italic>P</italic> = .13).</p>
<p>On the basis of only 2 of these early studies,<sup><xref ref-type="bibr" rid="bibr17-0884533611434116">17</xref>,<xref ref-type="bibr" rid="bibr88-0884533611434116">88</xref></sup> a review on immunological therapy in sepsis concluded that further investigations into Se supplementation were warranted.<sup><xref ref-type="bibr" rid="bibr89-0884533611434116">89</xref></sup> Likewise, in 2004, a Cochrane review<sup><xref ref-type="bibr" rid="bibr90-0884533611434116">90</xref></sup> analyzed 7 trials involving 813 participants but concluded that there was insufficient evidence to recommend Se or ebselen (a synthetic organic Se compound) supplementation in ICU patients. Analysis of 4 of these studies using a random effects model revealed no significant improvement in outcome (relative risk [RR] = 0.52; 95% CI, 0.20–1.34), but with a fixed effects model, the Se treatment groups showed a significant decrease in mortality (RR = 0.46; 95% CI, 0.26–0.81).</p>
</sec>
<sec id="section7-0884533611434116">
<title>Supplementation With Antioxidant Cocktails, Including Selenium</title>
<p>The first meta-analysis on antioxidants in critically ill patients, published by the Canadian Critical Care Group (CCCG) in 2005,<sup><xref ref-type="bibr" rid="bibr16-0884533611434116">16</xref></sup> suggested that relatively low doses of Se (&lt;500 µg/d) were not associated with a decrease in mortality (RR = 1.47; 95% CI, 0.20–10.78; <italic>P</italic> = .70), whereas the small number of studies that used doses higher than 500 µg/d showed a tendency toward a decrease in mortality (RR = 0.52; 95% CI, 0.24–1.14; <italic>P</italic> = .10). The most current online evidence on supplementation with antioxidant cocktails (including Se) in the critically ill (n = 19 studies) confirms that this strategy is still associated with a positive mortality effect (RR = 0.81; 95% CI, 0.70–0.94; <italic>P</italic> = .004).<sup><xref ref-type="bibr" rid="bibr91-0884533611434116">91</xref></sup></p>
<p>Berger et al<sup><xref ref-type="bibr" rid="bibr92-0884533611434116">92</xref></sup> have aggregated 2 randomized, double-blind trials (from 1998 and 2004) involving 41 burned patients. The intervention groups received parenteral trace element supplements, including Se 315–380 µg/d (2.9–4.8 µmol/d) plus copper 2.5–3.1 mg/d and zinc 26.2–31.4 mg/d, for 8–21 days. Those patients had enhanced plasma Se and GPx levels in plasma and skin; in addition, a reduction of nosocomial pneumonia compared to controls (33% vs 80%, <italic>P</italic> &lt; .001) and fewer episodes of VAP (6 vs 13, <italic>P</italic> = .023) were reported. A subsequent prospective study from this Swiss group<sup><xref ref-type="bibr" rid="bibr93-0884533611434116">93</xref></sup> evaluated the effect of high-dose enteral glutamine (30 g/d) plus antioxidants (Se, zinc, β-carotene, and vitamins C, B<sub>1</sub>, and E) in 86 critically ill, burned, and major trauma patients. Enteral Se supplementation was 300 µg/d, and burned patients received an additional 485.5 µg/d i.v. selenite for a maximum of 10 days. This combination of enteral glutamine plus parenteral micronutrients (including a moderately high dose of Se) was reportedly safe but did not significantly improve clinical outcome. A similar parenteral antioxidant cocktail (zinc, vitamins C and B<sub>1</sub>, and Se 270 µg/d), given as a double loading dose on the first 2 days<sup><xref ref-type="bibr" rid="bibr94-0884533611434116">94</xref></sup> to 200 patients with organ failure after complicated cardiac surgery, major trauma, and subarachnoid hemorrhage, significantly reduced the inflammatory response in the intervention group (n = 102). A large retrospective analysis of 4294 trauma patients,<sup><xref ref-type="bibr" rid="bibr95-0884533611434116">95</xref></sup> half of whom had received an antioxidant mixture of parenteral vitamin C, enteral α-tocopherol, and Se (200 µg as a bolus over 2 hours) for 7 days showed a significantly shorter hospital and ICU length of stay (<italic>P</italic> &lt; .001 and <italic>P</italic> = .001, respectively), as well as lower mortality (6.1% vs 8.5%, <italic>P</italic> = .001) in the antioxidant group, which the authors translated into a 28% relative risk reduction for mortality.</p>
<p>A phase I dose-ranging study by Heyland et al<sup><xref ref-type="bibr" rid="bibr96-0884533611434116">96</xref></sup> has demonstrated that high-dose glutamine (0.35 g/kg parenterally plus 30 g enterally daily) and parenteral Se (500 µg) in combination with an enteral antioxidant cocktail (Se 300 µg plus zinc, β-carotene, vitamin C, vitamin E) is associated with an improvement in mitochondrial function (optimizing the mitochondrial/nuclear DNA ratio) and antioxidant capacity. Currently, the REDOXS study,<sup><xref ref-type="bibr" rid="bibr97-0884533611434116">97</xref></sup> a multicenter prospective double-blind randomized trial in 1200 ICU patients, is investigating the effect of this high-dose glutamine and antioxidant combination on mortality. Preliminary results from the first ICU patients (n = 102) with organ failure have shown that high doses of this pharmaconutrient cocktail can be safely administered via both the enteral and parenteral route.<sup><xref ref-type="bibr" rid="bibr98-0884533611434116">98</xref></sup> Meanwhile, a different combination of glutamine and Se incorporated into a standard PN regimen was investigated in the multicenter Scottish Intensive care Glutamine or seleNium Evaluative Trial (SIGNET).<sup><xref ref-type="bibr" rid="bibr99-0884533611434116">99</xref></sup> Four groups were randomized to receive (a) glutamine (0.2 g/kg/d), (b) sodium selenite (500 µg/d), (c) glutamine (0.2g/kg/d) plus Se (500 µg/d), or (d) PN with no additional glutamine or Se. None of the PN regimens had any effect on new infections or on mortality. However, there was a reduced incidence of new infections (OR = 0.53; 95% CI, 0.30–0.93) in the subgroup of patients who received PN supplemented with sodium selenite for at least 5 days.</p>
</sec>
<sec id="section8-0884533611434116">
<title>High-Dose Selenium Monotherapy</title>
<p>So far, the most important and significant investigation into Se supplementation as a single pharmaconutrient is the SIC study,<sup><xref ref-type="bibr" rid="bibr19-0884533611434116">19</xref></sup> a prospective, randomized, placebo-controlled trial in patients with severe SIRS, sepsis, and septic shock with an APACHE III &gt;70 from 11 German ICUs. Initially, 249 patients were randomized to receive either a 1000-µg bolus of sodium selenite on day 1 followed by a daily continuous infusion of a further 1000 µg for 14 days or a saline placebo. Out of these, 11 patients were excluded for various reasons, leaving 238 patients for the intention-to-treat analysis. Subsequently, a further 49 patients had to be excluded because of protocol deviations, bringing the total number of patients in the per-protocol analysis down to 189. Although the reduction in 28-day mortality for Se-supplemented patients failed to reach statistical significance in the intention-to-treat analysis (50.0% vs 39.7%; <italic>P</italic> = .109), mortality was significantly lower in the per-protocol group (56.7% vs 42.6%, <italic>P</italic> = .049). No toxicity or adverse effects from the high dose of Se were observed. It is very encouraging that the mortality rate was significantly reduced in the subgroups of severe sepsis patients with disseminated intravascular coagulation (<italic>P</italic> = .018), as well as in patients with more than 3 organ dysfunctions (<italic>P</italic> = .039) and in the most severely ill (APACHE III &gt;102) (<italic>P</italic> = .04).</p>
<p>A smaller, prospective, single-center study<sup><xref ref-type="bibr" rid="bibr100-0884533611434116">100</xref></sup> subsequently evaluated the effect of approximately half of this Se dose on biochemical markers and clinical outcome in 40 septic ICU patients. During 2 weeks, patients were randomized to receive i.v. sodium selenite supplementation, providing 474, 316, and 158 µg/d Se, for each of 3 consecutive days followed by a standard infusion of 31.6 µg (0.4 µmol)/d. Se supplementation did not reduce mortality or oxidative stress (as measured by F2 isoprostanes). However, there was a significant reduction in Sequential Organ Failure Assessment (SOFA) score with a significant negative correlation between plasma Se and SOFA (<italic>r</italic> = −0.36, <italic>P</italic> = .03).</p>
<p>Another multicenter, placebo-controlled, double-blind trial from Forceville et al<sup><xref ref-type="bibr" rid="bibr101-0884533611434116">101</xref></sup> enrolled 60 patients with septic shock. The authors safely infused the therapeutic group (n = 31) with a very high initial dose of sodium selenite (4000 µg [50.6 µmol] Se) as a continuous infusion in the first 24 hours (without an initial bolus loading dose), followed by 1000 µg/d for an additional 9 days (total Se: 13,000 µg [156 µmol per treatment]) but without improvement in clinical outcome. Mortality rates did not differ significantly between the test and control groups at any time point (45% vs 45%, <italic>P</italic> = .59, on day 28; 59% vs 68%, <italic>P</italic> = .32, at 6 months; 66% vs 71%, <italic>P</italic> = .43, at 1 year). This contrasts with the previous achievements by these investigators,<sup><xref ref-type="bibr" rid="bibr17-0884533611434116">17</xref></sup> leading to speculation that the different results are due to the omission of the initial pro-oxidant bolus loading dose of selenite. Animal data from the same research group<sup><xref ref-type="bibr" rid="bibr70-0884533611434116">70</xref></sup> have added further weight to this hypothesis.</p>
<p>Support for the initial bolus protocol is provided by ou<bold>r</bold> phase II, single-center prospective randomized controlled trial (PRCT) in SIRS patients with APACHE II ≥15. We have investigated high-dose selenious acid, administered first as a bolus, providing 2000 µg (25.3 µmol) Se over 2 h and thereafter 1600 µg/d (20.24 µmol) Se as a continuous infusion.<sup><xref ref-type="bibr" rid="bibr20-0884533611434116">20</xref></sup> After 10 days of therapy, SOFA scores decreased significantly in the selenite group (1.3 ± 1.2 vs 4.6 ± 2.0, <italic>P</italic> = .0001). In addition, the rates of early VAP (6.7% vs 37.5%, <italic>P</italic> = .04), and hospital-acquired pneumonia were lower after ICU discharge (<italic>P</italic> = .03). As previously observed, GPx-3 activity increased to a maximum at day 7 (0.62 ± 0.24 vs 0.28 ± 0.14 U/mL, <italic>P</italic> = .001) in the selenite and placebo groups, respectively, without any Se-related short-term adverse events (including respiratory failure, kidney injury, or hepatic dysfunction).</p>
<p>A recent PRCT<sup><xref ref-type="bibr" rid="bibr102-0884533611434116">102</xref></sup> of high-dose sodium selenite in 150 patients aimed to induce both pro- and antioxidant phases of the Se effect on a daily basis, by giving a loading dose of 1000 µg Se on day 1, followed by 500 µg on days 2–14 as a 30-minute rapid infusion, rather than as a prolonged continuous infusion. This approach also significantly increased Se and GPx-3 levels (<italic>P</italic> &lt; .001), without any serious high-dose Se-related adverse events such as seizures, refractory shock and acute lung injury. Markers of inflammation decreased similarly in both the intervention and the placebo groups, and a negative correlation was demonstrated between low-plasma Se and C-reactive protein (CRP; <italic>P</italic> = .035), procalcitonin (PCT; <italic>P</italic> = .022), and SOFA score (<italic>P</italic> = .001) at ICU admission but not at day 7 or day 14. The 28-day mortality was slightly, but not significantly, lower in the Se group (25% vs 32%), and neither was there a significant reduction of mortality in the subgroup analysis by severity of illness, but the authors admitted that their study was not sufficiently powered to determine this. There was, however, a trend toward reduced mortality in the most severely ill patients (APACHE II &gt;28). Finally, in the updated (online but unpublished) meta-analysis of Se supplementation studies by the CCCG, high-dose Se monotherapy providing 250–500 µg/d Se (n = 9) shows a trend toward mortality reduction (RR = 0.85; 95% CI, 0.72–1.01; <italic>P</italic> = .06),<sup><xref ref-type="bibr" rid="bibr91-0884533611434116">91</xref></sup> and the German<sup><xref ref-type="bibr" rid="bibr19-0884533611434116">19</xref></sup> and Uruguayan<sup><xref ref-type="bibr" rid="bibr20-0884533611434116">20</xref>,<xref ref-type="bibr" rid="bibr69-0884533611434116">69</xref></sup> higher dose studies (1000–1600 µg/d Se) using an initial bolus are associated with decreased rates of VAP, mortality, and SOFA scores (<xref ref-type="table" rid="table5-0884533611434116">Table 5</xref>).</p>
<table-wrap id="table5-0884533611434116" position="float">
<label>Table 5.</label>
<caption>
<p>Summary of the Most Relevant Pharmaconutrition Studies on Selenium (Selenite) Monotherapy</p>
</caption>
<graphic alt-version="no" alternate-form-of="table5-0884533611434116" position="float" xlink:href="10.1177_0884533611434116-table5.tif" xlink:type="simple"/>
<table>
<colgroup span="1">
<col align="left" span="1"/>
<col align="left" span="1"/>
<col align="left" span="1"/>
<col align="left" span="1"/>
</colgroup>
<thead>
<tr>
<th align="left" colspan="1" rowspan="1">Investigator Reference</th>
<th align="left" colspan="1" rowspan="1">Patient Population and Characteristics</th>
<th align="left" colspan="1" rowspan="1">Selenium Daily Dose (as Monotherapy)</th>
<th align="left" colspan="1" rowspan="1">Clinical Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="1" rowspan="1">Angstwurm et al (1999)<sup><xref ref-type="bibr" rid="bibr88-0884533611434116">88</xref></sup></td>
<td colspan="1" rowspan="1">Sepsis APACHE II &gt;15 (n = 42)</td>
<td colspan="1" rowspan="1">Days 1–3: 535 µg/d; days 4–6: 285 µg/d; days 7–9: 155 µg/d and then 35 µg/d</td>
<td colspan="1" rowspan="1">APACHE II was significantly lower (day 7, <italic>P</italic> = .018; and day 14, <italic>P</italic> = .045). CRRT requirement was less in the selenite group (<italic>P</italic> = .035).</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Angstwurm et al (2007)<sup><xref ref-type="bibr" rid="bibr19-0884533611434116">19</xref></sup></td>
<td colspan="1" rowspan="1">Severe sepsis, septic shock<break/>APACHE III &gt;70 (n = 249)</td>
<td colspan="1" rowspan="1">Day 1: loading bolus 1000 µg in 30 min and then continuous infusion 1000 µg/d during 14 days</td>
<td colspan="1" rowspan="1">Twenty-eight-day mortality was lower (39.7% vs 50%, <italic>P</italic> = .109). In the per-protocol analysis (n = 189), the decrease was significant (<italic>P</italic> = .049).</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Mishra et al (2007)<sup><xref ref-type="bibr" rid="bibr100-0884533611434116">100</xref></sup></td>
<td colspan="1" rowspan="1">Severe sepsis<break/>APACHE II &gt;18 (n = 40)</td>
<td colspan="1" rowspan="1">Days 1–3: 474 mcg/d, days 4–6: 316 mcg/d, days 7–9: 158 mcg/d, days 9–14: 31.6 mcg/d by continuous infusion</td>
<td colspan="1" rowspan="1">Negative correlation between plasma Se and SOFA (<italic>r</italic> = −0.36, <italic>P</italic> = .03). No difference in 28-day mortality (<italic>P</italic> = .95). CRRT requirement no different between groups (<italic>P</italic> = .99).</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Forceville et al (2007)<sup><xref ref-type="bibr" rid="bibr101-0884533611434116">101</xref></sup></td>
<td colspan="1" rowspan="1">Severe sepsis/septic shock APACHE II &gt;25 (n = 60)</td>
<td colspan="1" rowspan="1">Day 1: loading infusion 4000 µg/24 h and then 1000 µg/d during 9 days</td>
<td colspan="1" rowspan="1">No effect on clinical outcome: time to vasopressor withdrawal, hospital and ICU LOS, duration of mechanical ventilation, and 28-day mortality (<italic>P</italic> = .59).</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Valenta et al (2011)<sup><xref ref-type="bibr" rid="bibr102-0884533611434116">102</xref></sup></td>
<td colspan="1" rowspan="1">Severe sepsis/SIRS APACHE II &gt;30 (n = 150)</td>
<td colspan="1" rowspan="1">Day 1: loading bolus 1000 µg in 30 min and then 30-min infusion 500 µg/d during days 2–14</td>
<td colspan="1" rowspan="1">Negative correlations between plasma Se: CRP (<italic>P</italic> = .035), PCT (<italic>P</italic> = .022), and SOFA (<italic>P</italic> = .001) at admission but not on day 7 or 14.</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Manzanares et al (2011)<sup><xref ref-type="bibr" rid="bibr20-0884533611434116">20</xref></sup></td>
<td colspan="1" rowspan="1">Severe sepsis/SIRS APACHE II &gt;23 (n = 35)</td>
<td colspan="1" rowspan="1">Day 1: loading bolus: 2000 µg in 2 h and thereafter continuous infusion 1600 µg/d during 10 days</td>
<td colspan="1" rowspan="1">SOFA score decreased significantly (1.3 ± 1.2 vs 4.6 ± 2.0, <italic>P</italic> = .0001). Early VAP rate was lower (6.7% vs 37.5%, <italic>P</italic> = .04). HAP was lower after ICU discharge (<italic>P</italic> = .03).</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn4-0884533611434116">
<p>APACHE II and III, Acute Physiology and Chronic Health Evaluation II and III; CRP, C-reactive protein; CRRT, continuous renal replacement therapy; HAP, hospital-acquired pneumonia; ICU, intensive care unit; LOS, length of stay; PCT, procalcitonin; RRT, renal replacement therapy; SIRS, systemic inflammatory response syndrome; SOFA, sequential organ failure assessment; VAP, ventilator-associated pneumonia.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<sec id="section9-0884533611434116">
<title>Personalized Selenium Pharmaconutrition</title>
<p>Variants in selenoprotein genes corresponding to promoter, coding region, or 3′UTR have been identified and shown to cause functional changes. Selenoprotein function can differ between individuals in the following ways: (a) different dietary intakes affect Se protein synthesis and activity, (b) variants in a selenoprotein gene (mutations or single-nucleotide polymorphisms [SNPs]) lead to altered protein function or regulation, or (c) a combination of both (a) and (b). For example, a mutation in a Se-related gene causes an amino acid change, which alters SeC incorporation into selenoproteins and results in impaired thyroid function.<sup><xref ref-type="bibr" rid="bibr103-0884533611434116">103</xref></sup> Links between common SNPs, alone or in combination with insufficient dietary Se intake, and risk of disease related to this remain to be investigated. One well-identified SNP in a selenoprotein causes a proline and leucine amino acid change in GPx1, which alters enzyme activity<sup><xref ref-type="bibr" rid="bibr104-0884533611434116">104</xref></sup> and the relationship between plasma Se and RBC GPx1 activity.<sup><xref ref-type="bibr" rid="bibr105-0884533611434116">105</xref></sup> Other SNPs affect SePP function with altered responses of blood cell GPx1, GPX4, and TR1 to Se supplementation.</p>
<p>Because SePP has a key role in Se transport, any variants in the gene would influence risk of certain diseases and stress situations in which Se deficiencies have been implicated as determining factors. However, a number of SNPs in selenoprotein genes have functional consequences in outcome and risk. More extensive studies of larger cohorts that incorporate analysis of SNPs to assess variation across the selenoprotein pathway in combination with Se status and different levels of Se supplementation are worthy of future research.<sup><xref ref-type="bibr" rid="bibr106-0884533611434116">106</xref></sup> Better patient selection and/or dose effect phase II studies are necessary to establish the optimum safe pharmaconutrient dose and mode of administration before further phase III clinical trials are planned and conducted.</p>
</sec>
</sec>
<sec id="section10-0884533611434116">
<title>Conclusion</title>
<p>Critical illness with systemic inflammation is characterized by Se deficiency in clinical scenarios such as severe sepsis and septic shock. In this review, we have highlighted the role of Se supplementation in SIRS and sepsis. In these Se-deficient critically ill patients, high-dose Se protocols, incorporating a bolus injection followed by continuous infusion, appears to be safe for optimization of plasma levels and extracellular glutathione peroxidase antioxidant activity. This pharmaconutrition strategy has been associated with improvements in clinical outcomes such as illness severity and infectious complications. Laboratory measurements of Se are not routine, but we have proposed that Se status can be used as a predictor of outcome, and therefore early assessment of Se status should become mandatory in all ICUs. We hope and predict that in the near future, selenium supplementation will be a cost-effective and essential part of intensive care bundles for these critically ill patients. However, further dosing studies are necessary to optimize the improvements in antioxidant status and clinical benefits of selenium supplementation by i.v. bolus plus continuous infusion for SIRS patients.</p>
<p>Greater understanding of the relationship between selenoproteins and genetic variants will be facilitated by a more complete interpretation of the complex functions of selenoenzymes and their catalytic interactions with other metabolites. The impacts of genotype and polymorphisms are key components of a personalized pharmaconutrition to improve therapeutic clinical practice. Better biomarkers are required to ascertain optimum Se posology for individual critically ill patients, and clinical practice guidelines need further refinement. We nevertheless believe that sufficient evidence has been presented to consider initiating high-dose i.v. selenium supplementation (between 500 and 1600 µg/d), perhaps calculated on the basis of BMI, immediately on admission to the ICU for up to 14 days.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure">
<p>Financial disclosure: none declared.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0884533611434116">
<label>1.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Schwarz</surname><given-names>K</given-names></name>
<name name-style="western"><surname>Foltz</surname><given-names>CM.</given-names></name>
</person-group> <article-title>Selenium as an integral part of factor 3 against dietary liver necrotic degeneration</article-title>. <source>J Am Chem Soc</source>. <year>1957</year>;<volume>79</volume>:<fpage>3292</fpage>-<lpage>3293</lpage>.</citation>
</ref>
<ref id="bibr2-0884533611434116">
<label>2.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Geoghegan</surname><given-names>M</given-names></name>
<name name-style="western"><surname>McAuley</surname><given-names>D</given-names></name>
<name name-style="western"><surname>Eaton</surname><given-names>S</given-names></name><etal/>
</person-group>. <article-title>Selenium in critical illness</article-title>. <source>Curr Opin Crit Care</source>. <year>2006</year>;<volume>12</volume>:<fpage>136</fpage>-<lpage>141</lpage>.</citation>
</ref>
<ref id="bibr3-0884533611434116">
<label>3.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Rayman</surname><given-names>MP.</given-names></name>
</person-group> <article-title>The importance of selenium to human health</article-title>. <source>Lancet</source>. <year>2000</year>;<volume>356</volume>:<fpage>233</fpage>-<lpage>241</lpage>.</citation>
</ref>
<ref id="bibr4-0884533611434116">
<label>4.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Hardy</surname><given-names>G</given-names></name>
<name name-style="western"><surname>Hardy</surname><given-names>I.</given-names></name>
</person-group> <article-title>Selenium: the Se-XY nutraceutical</article-title>. <source>Nutrition</source>. <year>2004</year>;<volume>20</volume>:<fpage>590</fpage>-<lpage>593</lpage>.</citation>
</ref>
<ref id="bibr5-0884533611434116">
<label>5.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Berger</surname><given-names>MM.</given-names></name>
</person-group> <article-title>Can oxidative damage be treated nutritionally?</article-title> <source>Clin Nutr</source>. <year>2005</year>;<volume>24</volume>:<fpage>172</fpage>-<lpage>183</lpage>.</citation>
</ref>
<ref id="bibr6-0884533611434116">
<label>6.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Dodig</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Cepelak</surname><given-names>I.</given-names></name>
</person-group> <article-title>The facts and controversy about selenium</article-title>. <source>Acta Pharm</source>. <year>2004</year>;<volume>54</volume>:<fpage>261</fpage>-<lpage>276</lpage>.</citation>
</ref>
<ref id="bibr7-0884533611434116">
<label>7.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Reid</surname><given-names>ME</given-names></name>
<name name-style="western"><surname>Duffield-Lillico</surname><given-names>AJ</given-names></name>
<name name-style="western"><surname>Sunga</surname><given-names>A</given-names></name><etal/>
</person-group>. <article-title>Selenium supplementation and colorectal adenomas: an analysis of the nutritional prevention of cancer trial</article-title>. <source>Int J Cancer</source>. <year>2006</year>;<volume>118</volume>:<fpage>1777</fpage>-<lpage>1781</lpage>.</citation>
</ref>
<ref id="bibr8-0884533611434116">
<label>8.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Fairweather-Tait</surname><given-names>SJ</given-names></name>
<name name-style="western"><surname>Bao</surname><given-names>Y</given-names></name>
<name name-style="western"><surname>Broadley</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>Selenium in human health and disease</article-title>. <source>Antioxid Redox Signal</source>. <year>2011</year>;<volume>14</volume>:<fpage>1337</fpage>-<lpage>1383</lpage>.</citation>
</ref>
<ref id="bibr9-0884533611434116">
<label>9.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Fordyce</surname><given-names>F.</given-names></name>
</person-group> <article-title>Selenium geochemistry and health</article-title>. <source>Ambio</source>. <year>2007</year>;<volume>36</volume>:<fpage>94</fpage>-<lpage>97</lpage>.</citation>
</ref>
<ref id="bibr10-0884533611434116">
<label>10.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Rayman</surname><given-names>MP.</given-names></name>
</person-group> <article-title>Food-chain selenium and human health</article-title>. <source>Br J Nutr</source>. <year>2008</year>;<volume>100</volume>:<fpage>254</fpage>-<lpage>268</lpage>.</citation>
</ref>
<ref id="bibr11-0884533611434116">
<label>11.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Flynn</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Hirvonen</surname><given-names>T</given-names></name>
<name name-style="western"><surname>Mensink</surname><given-names>GBM</given-names></name>
<etal/>
</person-group>. <article-title>Intake of selected nutrients from foods, from fortification and from supplements in various European countries</article-title>. <source>Food Nutr Res</source>. <year>2009</year>;<volume>12</volume>(<supplement>suppl 1</supplement>):<fpage>1</fpage>-<lpage>53</lpage>.</citation>
</ref>
<ref id="bibr12-0884533611434116">
<label>12.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Thomson</surname><given-names>CD.</given-names></name>
</person-group> <article-title>Selenium and iodine intakes and status in New Zealand and Australia</article-title>. <source>Br J Nutr</source>. <year>2004</year>;<volume>91</volume>:<fpage>661</fpage>-<lpage>672</lpage>.</citation>
</ref>
<ref id="bibr13-0884533611434116">
<label>13.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Forman</surname><given-names>HJ</given-names></name>
<name name-style="western"><surname>Torres</surname><given-names>M.</given-names></name>
</person-group> <article-title>Reactive oxygen species and cell signalling: respiratory burst in macrophage signaling</article-title>. <source>Am J Resp Crit Care Med</source>. <year>2002</year>;<volume>166</volume>:<fpage>S4</fpage>-<lpage>S8</lpage>.</citation>
</ref>
<ref id="bibr14-0884533611434116">
<label>14.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Tolando</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Jovanovic</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Brigelius-Flohé</surname><given-names>R</given-names></name>
<etal/>
</person-group>. <article-title>Reactive oxygen species and proinflammatory cytokine signaling in endothelial cells: effects of selenium supplementation</article-title>. <source>Free Radic Biol Med</source>. <year>2000</year>;<volume>15</volume>:<fpage>979</fpage>-<lpage>986</lpage>.</citation>
</ref>
<ref id="bibr15-0884533611434116">
<label>15.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Steinbrenner</surname><given-names>H</given-names></name>
<name name-style="western"><surname>Sies</surname><given-names>H.</given-names></name>
</person-group> <article-title>Protection against reactive oxygen species by selenoproteins</article-title>. <source>Biochim Biophys Acta</source>. <year>2009</year>;<volume>1790</volume>:<fpage>1478</fpage>-<lpage>1485</lpage>.</citation>
</ref>
<ref id="bibr16-0884533611434116">
<label>16.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Heyland</surname><given-names>DK</given-names></name>
<name name-style="western"><surname>Dhaliwal</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Suchner</surname><given-names>U</given-names></name>
<etal/>
</person-group>. <article-title>Antioxidants nutrients: a systematic review of trace elements and vitamins in the critically ill patient</article-title>. <source>Intensive Care Med</source>. <year>2005</year>;<volume>31</volume>:<fpage>327</fpage>-<lpage>337</lpage>.</citation>
</ref>
<ref id="bibr17-0884533611434116">
<label>17.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Forceville</surname><given-names>X</given-names></name>
<name name-style="western"><surname>Vitoux</surname><given-names>D</given-names></name>
<name name-style="western"><surname>Gauzit</surname><given-names>R</given-names></name>
<etal/>
</person-group>. <article-title>Selenium, systemic immune response syndrome, sepsis and outcome in critically ill patients</article-title>. <source>Crit Care Med</source>. <year>1998</year>;<volume>26</volume>:<fpage>1536</fpage>-<lpage>1544</lpage>.</citation>
</ref>
<ref id="bibr18-0884533611434116">
<label>18.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Manzanares</surname><given-names>W</given-names></name>
<name name-style="western"><surname>Hardy</surname><given-names>G.</given-names></name>
</person-group> <article-title>Selenium supplementation in the critically ill: posology and pharmacokinetics</article-title>. <source>Curr Opin Clin Nutr Metab Care</source>. <year>2009</year>;<volume>12</volume>:<fpage>273</fpage>-<lpage>280</lpage>.</citation>
</ref>
<ref id="bibr19-0884533611434116">
<label>19.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Angstwurm</surname><given-names>MWA</given-names></name>
<name name-style="western"><surname>Engelmann</surname><given-names>L</given-names></name>
<name name-style="western"><surname>Zimmermann</surname><given-names>T</given-names></name>
<etal/>
</person-group>. <article-title>Selenium in Intensive Care (SIC) study: results of a prospective, randomized, placebo-controlled, multiple-centre study in patients with severe systemic inflammatory response syndrome, sepsis and septic shock</article-title>. <source>Crit Care Med</source>. <year>2007</year>;<volume>35</volume>:<fpage>118</fpage>-<lpage>126</lpage>.</citation>
</ref>
<ref id="bibr20-0884533611434116">
<label>20.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Manzanares</surname><given-names>W</given-names></name>
<name name-style="western"><surname>Biestro</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Torre</surname><given-names>MH</given-names></name>
<etal/>
</person-group>. <article-title>High dose selenium reduces ventilator associated pneumonia and illness severity in critically ill patients with systemic inflammation</article-title>. <source>Intensive Care Med</source>. <year>2011</year>;<volume>37</volume>:<fpage>1120</fpage>-<lpage>1127</lpage>.</citation>
</ref>
<ref id="bibr21-0884533611434116">
<label>21.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Martindale</surname><given-names>RG</given-names></name>
<name name-style="western"><surname>McClave</surname><given-names>SA</given-names></name>
<name name-style="western"><surname>Vanek</surname><given-names>VW</given-names></name>
<etal/>
</person-group>. <article-title>Guidelines for the provision of nutrition support therapy in the adult critically ill patient: Society of Critical Care Medicine and A.S.P.E.N</article-title>. <source>Crit Care Med</source>. <year>2009</year>;<volume>37</volume>:<fpage>1757</fpage>-<lpage>1761</lpage>.</citation>
</ref>
<ref id="bibr22-0884533611434116">
<label>22.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Singer</surname><given-names>P</given-names></name>
<name name-style="western"><surname>Berger</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Van den Berghe</surname><given-names>G</given-names></name>
<etal/>
</person-group>. <article-title>ESPEN guidelines on parenteral nutrition: intensive care</article-title>. <source>Clin Nutr</source>. <year>2009</year>:<volume>28</volume>;<fpage>387</fpage>-<lpage>400</lpage>.</citation>
</ref>
<ref id="bibr23-0884533611434116">
<label>23.</label>
<citation citation-type="book" xlink:type="simple">
<person-group person-group-type="editor">
<name name-style="western"><surname>Otter</surname><given-names>JJ</given-names></name>
<name name-style="western"><surname>Pitze-Hellwig</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Meyers</surname><given-names>LO</given-names></name>
</person-group>, eds. <article-title>Institute of Medicine of the National Academies</article-title>. <source>Dietary Reference Intakes: The Essential Guide to Nutrient Requirements</source>. <publisher-loc>Washington, DC</publisher-loc>: <publisher-name>National Academic Press</publisher-name>; <year>2006</year>.</citation>
</ref>
<ref id="bibr24-0884533611434116">
<label>24.</label>
<citation citation-type="book" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Shenkin</surname><given-names>A</given-names></name>
</person-group>. <article-title>Trace elements and vitamins in parenteral and enteral nutrition</article-title>. In: <person-group person-group-type="editor">
<name name-style="western"><surname>Sobotka</surname><given-names>L</given-names></name>
</person-group>, ed. <source>Basics in Clinical Nutrition</source>. <publisher-loc>Prague, Czech Republic</publisher-loc>: <publisher-name>Galen</publisher-name>; <volume>2004</volume>:<fpage>169</fpage>-<lpage>175</lpage>.</citation>
</ref>
<ref id="bibr25-0884533611434116">
<label>25.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Sriram</surname><given-names>K</given-names></name>
<name name-style="western"><surname>Lonchyna</surname><given-names>VA.</given-names></name>
</person-group> <article-title>Micronutrient supplementation in adult nutrition therapy: practical considerations</article-title>. <source>JPEN J Parenter Enteral Nutr</source>. <year>2009</year>;<volume>33</volume>:<fpage>548</fpage>-<lpage>562</lpage>.</citation>
</ref>
<ref id="bibr26-0884533611434116">
<label>26.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Mirtallo</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Canada</surname><given-names>T</given-names></name>
<name name-style="western"><surname>Johnson</surname><given-names>D</given-names></name>
<etal/>
</person-group>. <article-title>Safe practices for parenteral nutrition</article-title>. <source>JPEN J Parenter Enteral Nutr</source>. <year>2004</year>;<volume>28</volume>:<fpage>S39</fpage>-<lpage>S69</lpage>.</citation>
</ref>
<ref id="bibr27-0884533611434116">
<label>27.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Lu</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Holmgren</surname><given-names>A.</given-names></name>
</person-group> <article-title>Selenoproteins</article-title>. <source>J Biol Chem</source>. <year>2009</year>;<volume>284</volume>:<fpage>723</fpage>-<lpage>727</lpage>.</citation>
</ref>
<ref id="bibr28-0884533611434116">
<label>28.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Squires</surname><given-names>JE</given-names></name>
<name name-style="western"><surname>Berry</surname><given-names>MJ.</given-names></name>
</person-group> <article-title>Eukaryotic selenoproteins synthesis: mechanistic insight incorporating new factors and new functions for old factors</article-title>. <source>IUBMB Life</source>. <year>2008</year>;<volume>60</volume>:<fpage>232</fpage>-<lpage>235</lpage>.</citation>
</ref>
<ref id="bibr29-0884533611434116">
<label>29.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Moghadaszadeh</surname><given-names>B</given-names></name>
<name name-style="western"><surname>Beggs</surname><given-names>AH.</given-names></name>
</person-group> <article-title>Selenoproteins and their impact on human health through diverse physiological pathways</article-title>. <source>Physiology</source>. <year>2006</year>;<volume>21</volume>: <fpage>307</fpage>-<lpage>315</lpage>.</citation>
</ref>
<ref id="bibr30-0884533611434116">
<label>30.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Bierl</surname><given-names>C</given-names></name>
<name name-style="western"><surname>Voetsch</surname><given-names>B</given-names></name>
<name name-style="western"><surname>Jin</surname><given-names>RC</given-names></name>
<etal/>
</person-group>. <article-title>Determinants of human plasma glutathione peroxidase-3 expression</article-title>. <source>J Biol Chem</source>. <year>2004</year>;<volume>279</volume>:<fpage>26839</fpage>-<lpage>26845</lpage>.</citation>
</ref>
<ref id="bibr31-0884533611434116">
<label>31.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Westphal</surname><given-names>K</given-names></name>
<name name-style="western"><surname>Stangl</surname><given-names>V</given-names></name>
<name name-style="western"><surname>Fähling</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>Human-specific induction of glutathione peroxidase-3 by proteosome inhibition in cardiovascular cells</article-title>. <source>Free Radic Biol Med</source>. <year>2009</year>;<volume>47</volume>:<fpage>1652</fpage>-<lpage>1660</lpage>.</citation>
</ref>
<ref id="bibr32-0884533611434116">
<label>32.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Hill</surname><given-names>KE</given-names></name>
<name name-style="western"><surname>Burk</surname><given-names>RF.</given-names></name>
</person-group> <article-title>Selenoprotein P: recent studies in rats and in humans</article-title>. <source>Biomed Environ Sci</source>. <year>1997</year>;<volume>10</volume>:<fpage>198</fpage>-<lpage>208</lpage>.</citation>
</ref>
<ref id="bibr33-0884533611434116">
<label>33.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Mostert</surname><given-names>V.</given-names></name>
</person-group> <article-title>Selenoprotein P: properties, functions, and regulation</article-title>. <source>Arch Biochem Biophys</source>. <year>2000</year>;<volume>376</volume>:<fpage>433</fpage>-<lpage>438</lpage>.</citation>
</ref>
<ref id="bibr34-0884533611434116">
<label>34.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Burk</surname><given-names>RF</given-names></name>
<name name-style="western"><surname>Hill</surname><given-names>KE.</given-names></name>
</person-group> <article-title>Selenoprotein P: an extracelular protein with unique physical characteristics and role in selenium homeostasis</article-title>. <source>Ann Rev Nutr</source>. <year>2005</year>;<volume>25</volume>:<fpage>2125</fpage>-<lpage>235</lpage>.</citation>
</ref>
<ref id="bibr35-0884533611434116">
<label>35.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Papp</surname><given-names>LV</given-names></name>
<name name-style="western"><surname>Lu</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Holmgren</surname><given-names>A</given-names></name>
<etal/>
</person-group>. <article-title>From selenium to selenoproteins: synthesis, identity and their role in human health</article-title>. <source>Antioxid Redox Signal</source>. <year>2007</year>;<volume>9</volume>:<fpage>775</fpage>-<lpage>806</lpage>.</citation>
</ref>
<ref id="bibr36-0884533611434116">
<label>36.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Hill</surname><given-names>KE</given-names></name>
<name name-style="western"><surname>Xia</surname><given-names>Y</given-names></name>
<name name-style="western"><surname>Akesson</surname><given-names>B</given-names></name>
<etal/>
</person-group>. <article-title>Selenoprotein P concentration in plasma is an index of selenium status in selenium deficient and selenium supplemented Chinese subjects</article-title>. <source>J Nutr</source>. <year>1996</year>;<volume>126</volume>:<fpage>138</fpage>-<lpage>145</lpage>.</citation>
</ref>
<ref id="bibr37-0884533611434116">
<label>37.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Nickel</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Kottra</surname><given-names>G</given-names></name>
<name name-style="western"><surname>Schmidt</surname><given-names>G</given-names></name>
<etal/>
</person-group>. <article-title>Characteristics of transport of selenoamino acids by epithelial amino acid transporters</article-title>. <source>Chem Biol Interact</source>. <year>2009</year>;<volume>177</volume>:<fpage>234</fpage>-<lpage>241</lpage>.</citation>
</ref>
<ref id="bibr38-0884533611434116">
<label>38.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Angstwurm</surname><given-names>MW</given-names></name>
<name name-style="western"><surname>Schopohl</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Gaertner</surname><given-names>R.</given-names></name>
</person-group> <article-title>Selenium substitution has no direct effect on thyroid hormone metabolism in critically ill patients</article-title>. <source>Eur J Endocrinol</source>. <year>2004</year>;<volume>151</volume>:<fpage>47</fpage>-<lpage>54</lpage>.</citation>
</ref>
<ref id="bibr39-0884533611434116">
<label>39.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Berger</surname><given-names>MM</given-names></name>
<name name-style="western"><surname>Reymond</surname><given-names>MJ</given-names></name>
<name name-style="western"><surname>Shenkin</surname><given-names>A</given-names></name>
<etal/>
</person-group>. <article-title>Influence of selenium supplements on the post-traumatic alterations of the thyroid axis: a placebo-controlled trial</article-title>. <source>Intensive Care Med</source>. <year>2001</year>;<volume>27</volume>:<fpage>91</fpage>-<lpage>100</lpage>.</citation>
</ref>
<ref id="bibr40-0884533611434116">
<label>40.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Rennie</surname><given-names>KL</given-names></name>
<name name-style="western"><surname>Croward</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Jebb</surname><given-names>SA.</given-names></name>
</person-group> <article-title>Estimating under reporting of energy intake in dietary surveys using an individualised method</article-title>. <source>Br J Nutr</source>. <year>2007</year>;<volume>97</volume>:<fpage>1169</fpage>-<lpage>1176</lpage>.</citation>
</ref>
<ref id="bibr41-0884533611434116">
<label>41.</label>
<citation citation-type="book" xlink:type="simple">
<collab xlink:type="simple">World Health Organization (WHO), Food and Agriculture Organization</collab>. <source>Trace Elements in Human Nutrition</source>. <publisher-loc>Geneva, Switzerland</publisher-loc>: <publisher-name>WHO</publisher-name>; <year>1996</year>.</citation>
</ref>
<ref id="bibr42-0884533611434116">
<label>42.</label>
<citation citation-type="book" xlink:type="simple">
<collab xlink:type="simple">World Health Organization (WHO), Food and Agriculture Organization</collab>. <source>Trace Elements in Human Nutrition</source>. <publisher-loc>Geneva, Switzerland</publisher-loc>: <publisher-name>WHO</publisher-name>; <year>2006</year>.</citation>
</ref>
<ref id="bibr43-0884533611434116">
<label>43.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Manzanares</surname><given-names>W</given-names></name>
<name name-style="western"><surname>Biestro</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Galusso</surname><given-names>F</given-names></name>
<etal/>
</person-group>. <article-title>Serum selenium and glutathione peroxidase-3 activity: biomarkers of systemic inflammation in the critically ill</article-title>. <source>Intensive Care Med</source>. <year>2009</year>;<volume>35</volume>:<fpage>882</fpage>-<lpage>889</lpage>.</citation>
</ref>
<ref id="bibr44-0884533611434116">
<label>44.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Vincent</surname><given-names>JL</given-names></name>
<name name-style="western"><surname>Forceville</surname><given-names>X.</given-names></name>
</person-group> <article-title>Critically elucidating the role of selenium</article-title>. <source>Curr Opin Anesthesiol</source>. <year>2008</year>;<volume>21</volume>:<fpage>148</fpage>-<lpage>154</lpage>.</citation>
</ref>
<ref id="bibr45-0884533611434116">
<label>45.</label>
<citation citation-type="book" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Forceville</surname><given-names>X</given-names></name>
<name name-style="western"><surname>Van Antwerpen</surname><given-names>P</given-names></name>
</person-group>. <article-title>Selenocompounds and selenium: a biochemical approach to sepsis</article-title>. In: <person-group person-group-type="editor">
<name name-style="western"><surname>Vincent</surname><given-names>JL</given-names></name>
</person-group>, ed. <source>2008 Yearbook in Intensive Care and Emergency Medicine</source>. <publisher-loc>Berlin</publisher-loc>: <publisher-name>Springer-Verlag</publisher-name>; <volume>2008</volume>:<fpage>454</fpage>-<lpage>466</lpage>.</citation>
</ref>
<ref id="bibr46-0884533611434116">
<label>46.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Ashton</surname><given-names>K</given-names></name>
<name name-style="western"><surname>Hooper</surname><given-names>L</given-names></name>
<name name-style="western"><surname>Harvey</surname><given-names>LJ</given-names></name>
<etal/>
</person-group>. <article-title>Methods of assessment of selenium status in humans: a systematic review</article-title>. <source>Am J Clin Nutr</source>. <year>2009</year>;<volume>89</volume>:2025S-2039S.</citation>
</ref>
<ref id="bibr47-0884533611434116">
<label>47.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Van Cauwenbergh</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Robberecht</surname><given-names>H</given-names></name>
<name name-style="western"><surname>Van Vlaslaer</surname><given-names>V</given-names></name>
<etal/>
</person-group>. <article-title>Comparison of serum selenium content of healthy adults living in the Antwerp region (Belgium) with recent literature data</article-title>. <source>J Trace Elem Med Biol</source>. <year>2004</year>;<volume>18</volume>: <fpage>99</fpage>-<lpage>112</lpage>.</citation>
</ref>
<ref id="bibr48-0884533611434116">
<label>48.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Cheung</surname><given-names>MC</given-names></name>
<name name-style="western"><surname>Zhao</surname><given-names>XQ</given-names></name>
<name name-style="western"><surname>Chait</surname><given-names>A</given-names></name>
<etal/>
</person-group>. <article-title>Antioxidants supplements block the response of HDL to simvastatin-niacin therapy in patients with coronary artery disease</article-title>. <source>Arterioscler Thromb Vasc Biol</source>. <year>2001</year>;<volume>21</volume>:<fpage>1320</fpage>-<lpage>1326</lpage>.</citation>
</ref>
<ref id="bibr49-0884533611434116">
<label>49.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Peretz</surname><given-names>AM</given-names></name>
<name name-style="western"><surname>Neve</surname><given-names>JD</given-names></name>
<name name-style="western"><surname>Famaey</surname><given-names>JP.</given-names></name>
</person-group> <article-title>Selenium in rheumatic diseases</article-title>. <source>Semin Arthritis Rheum</source>. <year>1991</year>;<volume>20</volume>:<fpage>305</fpage>-<lpage>316</lpage>.</citation>
</ref>
<ref id="bibr50-0884533611434116">
<label>50.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Van Gossum</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Nève</surname><given-names>J</given-names></name>
</person-group>. <article-title>Low selenium status in alcoholic cirrhosis is correlated with aminopyrine breath test: preliminary effects of selenium supplementation</article-title>. <source>Biol Trace Elem Res</source>. <year>1995</year>;<volume>47</volume>:<fpage>201</fpage>-<lpage>217</lpage>.</citation>
</ref>
<ref id="bibr51-0884533611434116">
<label>51.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Lecomte</surname><given-names>E</given-names></name>
<name name-style="western"><surname>Herbeth</surname><given-names>B</given-names></name>
<name name-style="western"><surname>Pirollet</surname><given-names>P</given-names></name>
<etal/>
</person-group>. <article-title>Effect of alcohol consumption on blood antioxidant nutrients and oxidative stress indicators</article-title>. <source>Am J Clin Nutr</source>. <year>1994</year>;<volume>60</volume>:<fpage>255</fpage>-<lpage>261</lpage>.</citation>
</ref>
<ref id="bibr52-0884533611434116">
<label>52.</label>
<citation citation-type="book" xlink:type="simple">
<person-group person-group-type="editor">
<name name-style="western"><surname>Shapses</surname><given-names>SA</given-names></name>
<name name-style="western"><surname>Schlussel</surname><given-names>YR</given-names></name>
<name name-style="western"><surname>Mariana</surname><given-names>C</given-names></name>
</person-group>. <article-title>Drug-nutrient interactions that impact on mineral status</article-title>. In <person-group person-group-type="editor">
<name name-style="western"><surname>Boullata</surname><given-names>JL</given-names></name>
<name name-style="western"><surname>Armenti</surname><given-names>VT</given-names></name>
</person-group>, eds. <source>Handbook of Drug-Nutrient Interactions</source>. <publisher-loc>Totowa, NJ</publisher-loc>: <publisher-name>Humana</publisher-name>; <volume>2010</volume>:<fpage>537</fpage>-<lpage>571</lpage>.</citation>
</ref>
<ref id="bibr53-0884533611434116">
<label>53.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Díaz Flores</surname><given-names>JF</given-names></name>
<name name-style="western"><surname>Sañudo</surname><given-names>RI</given-names></name>
<name name-style="western"><surname>Rodríguez</surname><given-names>EM</given-names></name>
<etal/>
</person-group>. <article-title>Serum concentration of macro and trace elements in the heroin addicts of the Canary Islands</article-title>. <source>J Trace Elem Med Biol</source>. <year>2004</year>;<volume>17</volume>:<fpage>235</fpage>-<lpage>242</lpage>.</citation>
</ref>
<ref id="bibr54-0884533611434116">
<label>54.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Hurst</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Armah</surname><given-names>CN</given-names></name>
<name name-style="western"><surname>Dainty</surname><given-names>JR</given-names></name>
<etal/>
</person-group>. <article-title>Establishing optimal selenium status: results of a randomized, double-blind, placebo-controlled trial</article-title>. <source>Am J Clin Nutr</source>. <year>2010</year>;<volume>91</volume>:<fpage>923</fpage>-<lpage>931</lpage>.</citation>
</ref>
<ref id="bibr55-0884533611434116">
<label>55.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Maehira</surname><given-names>F</given-names></name>
<name name-style="western"><surname>Luyo</surname><given-names>GA</given-names></name>
<name name-style="western"><surname>Miyagy</surname><given-names>I</given-names></name>
<etal/>
</person-group>. <article-title>Alterations of serum selenium concentration in the acute phase of pathological conditions</article-title>. <source>Clin Chim Acta</source>. <year>2002</year>;<volume>316</volume>:<fpage>137</fpage>-<lpage>146</lpage>.</citation>
</ref>
<ref id="bibr56-0884533611434116">
<label>56.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Berger</surname><given-names>MM</given-names></name>
<name name-style="western"><surname>Chiólero</surname><given-names>R.</given-names></name>
</person-group> <article-title>Antioxidant supplementation in sepsis and systemic inflammatory response syndrome</article-title>. <source>Crit Care Med</source>. <year>2007</year>;358 (<supplement>suppl</supplement>):<fpage>S584</fpage>-<lpage>S590</lpage>.</citation>
</ref>
<ref id="bibr57-0884533611434116">
<label>57.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Berger</surname><given-names>MM</given-names></name>
<name name-style="western"><surname>Shenkin</surname><given-names>A.</given-names></name>
</person-group> <article-title>Selenium in intensive care: probably not a magic bullet but an important adjuvant therapy</article-title>. <source>Crit Care Med</source>. <year>2007</year>;<volume>35</volume>:<fpage>306</fpage>-<lpage>307</lpage>.</citation>
</ref>
<ref id="bibr58-0884533611434116">
<label>58.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Berger</surname><given-names>MM</given-names></name>
<name name-style="western"><surname>Shenkin</surname><given-names>A.</given-names></name>
</person-group> <article-title>Update on clinical micronutrient supplementation studies in the critically ill</article-title>. <source>Curr Opin Clin Nutr Metab Care</source>. <year>2006</year>;<volume>9</volume>: <fpage>711</fpage>-<lpage>716</lpage>.</citation>
</ref>
<ref id="bibr59-0884533611434116">
<label>59.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Angstwurm</surname><given-names>MWA</given-names></name>
<name name-style="western"><surname>Gaertner</surname><given-names>R.</given-names></name>
</person-group> <article-title>Practicalities of selenium supplementation in critically ill patients</article-title>. <source>Curr Opin Clin Nutr Metab Care</source>. <year>2006</year>;<volume>9</volume>:<fpage>233</fpage>-<lpage>238</lpage>.</citation>
</ref>
<ref id="bibr60-0884533611434116">
<label>60.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Klein</surname><given-names>CJ</given-names></name>
<name name-style="western"><surname>Nielsen</surname><given-names>FH</given-names></name>
<name name-style="western"><surname>Moser-Veillon</surname><given-names>PB.</given-names></name>
</person-group> <article-title>Trace element loss in urine and effluent following traumatic injury</article-title>. <source>JPEN J Parenter Enteral Nutr</source>. <year>2008</year>;<volume>32</volume>:<fpage>129</fpage>-<lpage>139</lpage>.</citation>
</ref>
<ref id="bibr61-0884533611434116">
<label>61.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Forceville</surname><given-names>X</given-names></name>
<name name-style="western"><surname>Mostert</surname><given-names>V</given-names></name>
<name name-style="western"><surname>Pierantoni</surname><given-names>A</given-names></name>
<etal/>
</person-group>. <article-title>Selenoprotein P, rather than glutathione peroxidase, as a potential marker of septic shock and related syndromes</article-title>. <source>Eur Surg Res</source>. <year>2009</year>;<volume>43</volume>:<fpage>338</fpage>-<lpage>347</lpage>.</citation>
</ref>
<ref id="bibr62-0884533611434116">
<label>62.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Sakr</surname><given-names>Y</given-names></name>
<name name-style="western"><surname>Reinhart</surname><given-names>K</given-names></name>
<name name-style="western"><surname>Bloos</surname><given-names>F</given-names></name>
<etal/>
</person-group>. <article-title>Time course and relationship between plasma selenium concentrations, systemic inflammatory response, sepsis and multiorgan failure</article-title>. <source>Br J Anaesth</source>. <year>2007</year>;<volume>98</volume>:<fpage>775</fpage>-<lpage>784</lpage>.</citation>
</ref>
<ref id="bibr63-0884533611434116">
<label>63.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Stoppe</surname><given-names>C</given-names></name>
<name name-style="western"><surname>Shalte</surname><given-names>G</given-names></name>
<name name-style="western"><surname>Rossaint</surname><given-names>R</given-names></name>
<etal/>
</person-group>. <article-title>The intraoperative decrease of selenium is associated with the postoperative development of multiorgan dysfunction in cardiac surgical patients</article-title>. <source>Crit Care Med</source>. <year>2011</year>;<volume>39</volume>:<fpage>1879</fpage>-<lpage>1885</lpage>.</citation>
</ref>
<ref id="bibr64-0884533611434116">
<label>64.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Forceville</surname><given-names>X.</given-names></name>
</person-group> <article-title>Selenium and the ‘free’ electron, selenium—a trace to be followed in septic or inflammatory ICU patients?</article-title> <source>Intensive Care Med</source>. <year>2001</year>;<volume>27</volume>:<fpage>16</fpage>-<lpage>18</lpage>.</citation>
</ref>
<ref id="bibr65-0884533611434116">
<label>65.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Maehira</surname><given-names>F</given-names></name>
<name name-style="western"><surname>Miyagi</surname><given-names>I</given-names></name>
<name name-style="western"><surname>Eguchi</surname><given-names>Y.</given-names></name>
</person-group> <article-title>Selenium regulates transcription factor NF-κB activation during the acute phase reaction</article-title>. <source>Clin Chem Acta</source>. <year>2003</year>;<volume>334</volume>:<fpage>163</fpage>-<lpage>171</lpage>.</citation>
</ref>
<ref id="bibr66-0884533611434116">
<label>66.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Jeong</surname><given-names>DW</given-names></name>
<name name-style="western"><surname>Yoo</surname><given-names>MH</given-names></name>
<name name-style="western"><surname>Kim</surname><given-names>TS</given-names></name>
<etal/>
</person-group>. <article-title>Protection of mice from allergen-induced asthma by selenite: prevention of eosinophil infiltration by inhibition of NF–kappa B activation</article-title>. <source>J Biol Chem</source>. <year>2002</year>;<volume>277</volume>:<fpage>17871</fpage>-<lpage>17876</lpage>.</citation>
</ref>
<ref id="bibr67-0884533611434116">
<label>67.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Stewart</surname><given-names>MS</given-names></name>
<name name-style="western"><surname>Spallholz</surname><given-names>JE</given-names></name>
<name name-style="western"><surname>Neldner</surname><given-names>KH</given-names></name>
<etal/>
</person-group>. <article-title>Selenium compounds have disparate abilities to impose oxidative stress and induce apoptosis</article-title>. <source>Free Radic Biol Med</source>. <year>1999</year>;<volume>26</volume>:<fpage>42</fpage>-<lpage>48</lpage>.</citation>
</ref>
<ref id="bibr68-0884533611434116">
<label>68.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Chung</surname><given-names>YW</given-names></name>
<name name-style="western"><surname>Kim</surname><given-names>TS</given-names></name>
<name name-style="western"><surname>Lee</surname><given-names>SY</given-names></name>
<etal/>
</person-group>. <article-title>Selenite-induced apoptosis of osteoclasts mediated by the mitochondrial pathway</article-title>. <source>Toxicol Lett</source>. <year>2006</year>;<volume>160</volume>: <fpage>143</fpage>-<lpage>150</lpage>.</citation>
</ref>
<ref id="bibr69-0884533611434116">
<label>69.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Manzanares</surname><given-names>W</given-names></name>
<name name-style="western"><surname>Biestro</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Galusso</surname><given-names>F</given-names></name>
<etal/>
</person-group>. <article-title>High-dose selenium for critically ill patients with systemic inflammation: a pilot study</article-title>. <source>Nutrition</source>. <year>2010</year>;<volume>26</volume>:<fpage>634</fpage>-<lpage>640</lpage>.</citation>
</ref>
<ref id="bibr70-0884533611434116">
<label>70.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name>
<name name-style="western"><surname>Forceville</surname><given-names>X</given-names></name>
<name name-style="western"><surname>Van Antwerpen</surname><given-names>P</given-names></name>
<etal/>
</person-group>. <article-title>A large bolus, but not a continuous infusion, of sodium selenite improves outcome in peritonitis</article-title>. <source>Shock</source>. <year>2009</year>;<volume>32</volume>:<fpage>140</fpage>-<lpage>146</lpage>.</citation>
</ref>
<ref id="bibr71-0884533611434116">
<label>71.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Yang</surname><given-names>GQ</given-names></name>
<name name-style="western"><surname>Wang</surname><given-names>SZ</given-names></name>
<name name-style="western"><surname>Zhou</surname><given-names>RH</given-names></name>
<etal/>
</person-group>. <article-title>Endemic intoxication of humans in China</article-title>. <source>Am J Clin Nutr</source>. <year>1983</year>;<volume>37</volume>:<fpage>872</fpage>-<lpage>881</lpage>.</citation>
</ref>
<ref id="bibr72-0884533611434116">
<label>72.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Valdiglesias</surname><given-names>V</given-names></name>
<name name-style="western"><surname>Pésaro</surname><given-names>E</given-names></name>
<name name-style="western"><surname>Méndez</surname><given-names>J</given-names></name>
<etal/>
</person-group>. <article-title>In vitro evaluation of selenium genotoxic, cytotoxic and protective effect: a review</article-title>. <source>Arch Toxicol</source>. <year>2010</year>;<volume>84</volume>:<fpage>337</fpage>-<lpage>351</lpage>.</citation>
</ref>
<ref id="bibr73-0884533611434116">
<label>73.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Yang</surname><given-names>G</given-names></name>
<name name-style="western"><surname>Zhou</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Yin</surname><given-names>S</given-names></name>
<etal/>
</person-group>. <article-title>Studies of safe maximal daily dietary intake in a seleniferous area of China: selenium intake and tissue selenium levels of the inhabitants</article-title>. <source>J Trace Elem Elect Health Dis</source>. <year>1989</year>;<volume>3</volume>:<fpage>123</fpage>-<lpage>130</lpage>.</citation>
</ref>
<ref id="bibr74-0884533611434116">
<label>74.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Dhillon</surname><given-names>KS</given-names></name>
<name name-style="western"><surname>Dhillon</surname><given-names>SK</given-names></name>
<name name-style="western"><surname>Dogra</surname><given-names>R.</given-names></name>
</person-group> <article-title>Selenium accumulation by forage and grain crops and volatilization from seleniferous soils amended with different organic materials</article-title>. <source>Chemosphere</source>. <year>2010</year>;<volume>78</volume>:<fpage>548</fpage>-<lpage>556</lpage>.</citation>
</ref>
<ref id="bibr75-0884533611434116">
<label>75.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Hansen</surname><given-names>JC</given-names></name>
<name name-style="western"><surname>Pedersen</surname><given-names>HS.</given-names></name>
</person-group> <article-title>Environmental exposure to heavy metals in North Greenland</article-title>. <source>Arctic Med Res</source>. <year>1986</year>;<volume>41</volume>:<fpage>21</fpage>-<lpage>34</lpage>.</citation>
</ref>
<ref id="bibr76-0884533611434116">
<label>76.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Olson</surname><given-names>OE.</given-names></name>
</person-group> <article-title>Selenium toxicity in animals, with emphasis on man</article-title>. <source>J Am Coll Toxicol</source>. <year>1986</year>;<volume>5</volume>:<fpage>45</fpage>-<lpage>69</lpage>.</citation>
</ref>
<ref id="bibr77-0884533611434116">
<label>77.</label>
<citation citation-type="book" xlink:type="simple">
<collab xlink:type="simple">World Health Organization (WHO)</collab>. <source>Selenium, Environmental Health Criteria 58</source>. <publisher-loc>Geneva, Switzerland</publisher-loc>: <publisher-name>WHO</publisher-name>; <year>1987</year>.</citation>
</ref>
<ref id="bibr78-0884533611434116">
<label>78.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Glover</surname><given-names>JR</given-names></name>
<name name-style="western"><surname>Chu</surname><given-names>B.</given-names></name>
</person-group> <article-title>Selenium and its industrial toxicity</article-title>. <source>Indust Med Surg</source>. <year>1970</year>;<volume>39</volume>:<fpage>50</fpage>-<lpage>54</lpage>.</citation>
</ref>
<ref id="bibr79-0884533611434116">
<label>79.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Yang</surname><given-names>G</given-names></name>
<name name-style="western"><surname>Zhou</surname><given-names>R.</given-names></name>
</person-group> <article-title>Further observations on the human maximum safe dietary selenium intake in a seleniferous area of China</article-title>. <source>J Trace Elem Electrolytes Health Dis</source>. <year>1994</year>;<volume>8</volume>:<fpage>159</fpage>-<lpage>165</lpage>.</citation>
</ref>
<ref id="bibr80-0884533611434116">
<label>80.</label>
<citation citation-type="web" xlink:type="simple">
<collab xlink:type="simple">Scientific Committee on Food on the TUIL of Selenium</collab>. <source>Tolerable Upper Intake Levels of Selenium</source>. <comment><ext-link ext-link-type="uri" xlink:href="http://ec.europa.eu/food/fs/sc/scf/out80g_en.pdf" xlink:type="simple">http://ec.europa.eu/food/fs/sc/scf/out80g_en.pdf</ext-link></comment></citation>
</ref>
<ref id="bibr81-0884533611434116">
<label>81.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Shenkin</surname><given-names>A.</given-names></name>
</person-group> <article-title>Selenium in intravenous nutrition</article-title>. <source>Gastroenterology</source>. <year>2009</year>;<volume>137</volume>:<fpage>S61</fpage>-<lpage>S69</lpage>.</citation>
</ref>
<ref id="bibr82-0884533611434116">
<label>82.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Heyland</surname><given-names>DK.</given-names></name>
</person-group> <article-title>Selenium supplementation in critically ill patients: can too much of a good thing be a bad thing?</article-title> <source>Crit Care</source>. <year>2007</year>;<volume>11</volume>:<fpage>153</fpage>.</citation>
</ref>
<ref id="bibr83-0884533611434116">
<label>83.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Bopp</surname><given-names>BA</given-names></name>
<name name-style="western"><surname>Sonders</surname><given-names>RC</given-names></name>
<name name-style="western"><surname>Kesterson</surname><given-names>JW.</given-names></name>
</person-group> <article-title>Metabolic fate of selected selenium compounds in laboratory animals and man</article-title>. <source>Drug Metab Rev</source>. <year>1982</year>;<volume>13</volume>:<fpage>271</fpage>-<lpage>318</lpage>.</citation>
</ref>
<ref id="bibr84-0884533611434116">
<label>84.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Forceville</surname><given-names>X</given-names></name>
<name name-style="western"><surname>Chancerelle</surname><given-names>Y</given-names></name>
<name name-style="western"><surname>Agay</surname><given-names>D</given-names></name>
<etal/>
</person-group>. <article-title>At moderately high level, sodium selenium seems to decrease mortality in lipopolysaccharide rat model [abstract]</article-title>. <source>Intensive Care Med</source>. <year>2004</year>;<volume>30</volume>:<fpage>S110</fpage>.</citation>
</ref>
<ref id="bibr85-0884533611434116">
<label>85.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Andrews</surname><given-names>PJ.</given-names></name>
</person-group> <article-title>Selenium and glutamine supplements: where are we heading? A critical care perspective</article-title>. <source>Curr Opin Clin Nutr Metab Care</source>. <year>2010</year>;<volume>13</volume>: <fpage>192</fpage>-<lpage>197</lpage>.</citation>
</ref>
<ref id="bibr86-0884533611434116">
<label>86.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Kuklinski</surname><given-names>B</given-names></name>
<name name-style="western"><surname>Zimmermann</surname><given-names>T</given-names></name>
<name name-style="western"><surname>Schweder</surname><given-names>R.</given-names></name>
</person-group> <article-title>Decreasing mortality in acute pancreatitis with sodium selenite: clinical results of 4 years antioxidant therapy</article-title>. <source>Med Klin</source>. <year>1995</year>;<volume>90</volume>(<supplement>suppl 1</supplement>):<fpage>36</fpage>-<lpage>41</lpage>.</citation>
</ref>
<ref id="bibr87-0884533611434116">
<label>87.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Zimmermann</surname><given-names>T</given-names></name>
<name name-style="western"><surname>Albrecht</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Kuhne</surname><given-names>H</given-names></name>
<etal/>
</person-group>. <article-title>Selenium administration in patients with sepsis syndrome: a prospective randomized study</article-title>. <source>Med Klin</source>. <year>1997</year>;<volume>92</volume>:<fpage>3</fpage>-<lpage>4</lpage>.</citation>
</ref>
<ref id="bibr88-0884533611434116">
<label>88.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Angstwurm</surname><given-names>MA</given-names></name>
<name name-style="western"><surname>Schottdorf</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Schopohl</surname><given-names>J</given-names></name>
<etal/>
</person-group>. <article-title>Selenium replacement in patients with severe systemic inflammatory response syndrome improves clinical outcome</article-title>. <source>Crit Care Med</source>. <year>1999</year>;<volume>27</volume>:<fpage>1807</fpage>-<lpage>1813</lpage>.</citation>
</ref>
<ref id="bibr89-0884533611434116">
<label>89.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Carlet</surname><given-names>J</given-names></name>
</person-group>; <article-title>International Sepsis Forum. Immunological therapies in sepsis: current available</article-title>. <source>Intensive Care Med</source>. <year>2001</year>;<volume>27</volume>:<fpage>S93</fpage>-<lpage>S103</lpage>.</citation>
</ref>
<ref id="bibr90-0884533611434116">
<label>90.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Avenell</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Noble</surname><given-names>DW</given-names></name>
<name name-style="western"><surname>Barr</surname><given-names>J</given-names></name>
<etal/>
</person-group>. <article-title>Selenium supplementation for critically ill adults</article-title>. <source>Cochrane Database Syst Rev</source>. <year>2004</year>;(4):CD003703.</citation>
</ref>
<ref id="bibr91-0884533611434116">
<label>91.</label>
<citation citation-type="web" xlink:type="simple">
<collab xlink:type="simple">Critical Care Nutrition</collab>. <comment><ext-link ext-link-type="uri" xlink:href="http://www.criticalcarenutrition.com" xlink:type="simple">http://www.criticalcarenutrition.com</ext-link></comment></citation>
</ref>
<ref id="bibr92-0884533611434116">
<label>92.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Berger</surname><given-names>MM</given-names></name>
<name name-style="western"><surname>Eggimann</surname><given-names>P</given-names></name>
<name name-style="western"><surname>Heyland</surname><given-names>DK</given-names></name>
<etal/>
</person-group>. <article-title>Reduction of nosocomial pneumonia after major burns by trace element supplementation: aggregation of two randomised trials</article-title>. <source>Crit Care</source>. <year>2006</year>;<volume>10</volume>:<fpage>R153</fpage>.</citation>
</ref>
<ref id="bibr93-0884533611434116">
<label>93.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Soguel</surname><given-names>L</given-names></name>
<name name-style="western"><surname>Chiólero</surname><given-names>RL</given-names></name>
<name name-style="western"><surname>Ruffieux</surname><given-names>C</given-names></name>
<etal/>
</person-group>. <article-title>Monitoring the clinical introduction of a glutamine and antioxidant solution in critically ill trauma and burn patients</article-title>. <source>Nutrition</source>. <year>2008</year>;<volume>24</volume>:<fpage>1123</fpage>-<lpage>1132</lpage>.</citation>
</ref>
<ref id="bibr94-0884533611434116">
<label>94.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Berger</surname><given-names>MM</given-names></name>
<name name-style="western"><surname>Soguel</surname><given-names>L</given-names></name>
<name name-style="western"><surname>Shenkin</surname><given-names>A</given-names></name>
<etal/>
</person-group>. <article-title>Influence of early antioxidant supplements on clinical evolution and organ function in critically ill cardiac surgery, major trauma and subarachnoid hemorrhage patients</article-title>. <source>Crit Care</source>. <year>2008</year>;<volume>12</volume>:<fpage>R101</fpage>.</citation>
</ref>
<ref id="bibr95-0884533611434116">
<label>95.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Collier</surname><given-names>BR</given-names></name>
<name name-style="western"><surname>Giladi</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Dosset</surname><given-names>LA</given-names></name>
<etal/>
</person-group>. <article-title>Impact of high-dose antioxidants on outcomes in acutely injured patients</article-title>. <source>JPEN J Parenter Enteral Nutr</source>. <year>2008</year>;<volume>31</volume>:<fpage>384</fpage>-<lpage>388</lpage>.</citation>
</ref>
<ref id="bibr96-0884533611434116">
<label>96.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Heyland</surname><given-names>DK</given-names></name>
<name name-style="western"><surname>Dhaliwal</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Day</surname><given-names>A</given-names></name>
<etal/>
</person-group>. <article-title>Optimizing the dose of glutamine dipeptides and antioxidants in critically ill patients: a phase I dose-finding study</article-title>. <source>JPEN J Parenter Enteral Nutr</source>. <year>2007</year>;<volume>31</volume>:<fpage>109</fpage>-<lpage>118</lpage>.</citation>
</ref>
<ref id="bibr97-0884533611434116">
<label>97.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Heyland</surname><given-names>DK</given-names></name>
<name name-style="western"><surname>Dhaliwal</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Day</surname><given-names>AG</given-names></name>
<etal/>
</person-group>. <article-title>REducing Deaths due to OXidative Stress (the REDOXS study): rationale and study design for a randomized trial of glutamine and antioxidant supplementation in critically ill patients</article-title>. <source>Proc Nutr Soc</source>. <year>2006</year>;<volume>65</volume>:<fpage>250</fpage>-<lpage>263</lpage>.</citation>
</ref>
<ref id="bibr98-0884533611434116">
<label>98.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Dhaliwal</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Drover</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Muscedere</surname><given-names>J</given-names></name>
<etal/>
</person-group>. <article-title>The REDOXS study: feasibility of pharmaconutrition in critically ill patients</article-title>. <source>Clin Nutr</source>. <year>2008</year>;<volume>41</volume>(<supplement>suppl 1</supplement>):<fpage>P029</fpage>.</citation>
</ref>
<ref id="bibr99-0884533611434116">
<label>99.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Andrews</surname><given-names>PJD</given-names></name>
<name name-style="western"><surname>Avenell</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Noble</surname><given-names>DW</given-names></name>
<etal/>
</person-group>. <article-title>Randomised trial of glutamine, selenium, or both to supplement parenteral nutrition for critically ill patients</article-title>. <source>BMJ</source>. <year>2011</year>;<volume>342</volume>:<fpage>d1542</fpage>.</citation>
</ref>
<ref id="bibr100-0884533611434116">
<label>100.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Mishra</surname><given-names>V</given-names></name>
<name name-style="western"><surname>Baines</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Perry</surname><given-names>SE</given-names></name>
<etal/>
</person-group>. <article-title>Effect of selenium supplementation on biochemical markers and outcome in critically ill patients</article-title>. <source>Clin Nutr</source>. <year>2007</year>;<volume>26</volume>:<fpage>41</fpage>-<lpage>50</lpage>.</citation>
</ref>
<ref id="bibr101-0884533611434116">
<label>101.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Forceville</surname><given-names>X</given-names></name>
<name name-style="western"><surname>Laviolle</surname><given-names>B</given-names></name>
<name name-style="western"><surname>Annane</surname><given-names>D</given-names></name>
<etal/>
</person-group>. <article-title>Effects of high doses of selenium, as sodium selenite, in septic shock: a placebo-controlled, randomized, double-blind, phase II study</article-title>. <source>Crit Care</source>. <year>2007</year>;<volume>11</volume>:<fpage>R73</fpage>.</citation>
</ref>
<ref id="bibr102-0884533611434116">
<label>102.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Valenta</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Brodska</surname><given-names>H</given-names></name>
<name name-style="western"><surname>Drabek</surname><given-names>T</given-names></name>
<etal/>
</person-group>. <article-title>High-dose selenium substitution in sepsis: a prospective, randomized clinical trial</article-title>. <source>Intensive Care Med</source>. <year>2011</year>;<volume>37</volume>:<fpage>808</fpage>-<lpage>815</lpage>.</citation>
</ref>
<ref id="bibr103-0884533611434116">
<label>103.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Dumitrescu</surname><given-names>AM</given-names></name>
<name name-style="western"><surname>Liao</surname><given-names>XH</given-names></name>
<name name-style="western"><surname>Abdullah</surname><given-names>MS</given-names></name>
<etal/>
</person-group>. <article-title>Mutations in SECISBP2 result in abnormal thyroid hormone metabolism</article-title>. <source>Nat Genet</source>. <year>2005</year>;<volume>37</volume>:<fpage>1247</fpage>-<lpage>1252</lpage>.</citation>
</ref>
<ref id="bibr104-0884533611434116">
<label>104.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Forsberg</surname><given-names>L</given-names></name>
<name name-style="western"><surname>de Faire</surname><given-names>U</given-names></name>
<name name-style="western"><surname>Marklund</surname><given-names>SL</given-names></name>
<etal/>
</person-group>. <article-title>Phenotype determination of a common Pro-Leu polymorphism in human glutathione peroxidase-1</article-title>. <source>Blood Cells Mol Dis</source>. <year>2000</year>;<volume>26</volume>:<fpage>423</fpage>-<lpage>426</lpage>.</citation>
</ref>
<ref id="bibr105-0884533611434116">
<label>105.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Jablonska</surname><given-names>E</given-names></name>
<name name-style="western"><surname>Gromadzinska</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Reszka</surname><given-names>E</given-names></name>
<etal/>
</person-group>. <article-title>Association between GPx-1 Pro198Leu polymorphism, GPx-1 activity and plasma selenium concentration in humans</article-title>. <source>Eur J Nutr</source>. <year>2009</year>;<volume>48</volume>:<fpage>383</fpage>-<lpage>386</lpage>.</citation>
</ref>
<ref id="bibr106-0884533611434116">
<label>106.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Fairweather-Tait</surname><given-names>SJ</given-names></name>
<name name-style="western"><surname>Collings</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Hurst</surname><given-names>R.</given-names></name>
</person-group> <article-title>Selenium bioavailability: current knowledge and future research requirements</article-title>. <source>Am J Clin Nutr</source>. <year>2010</year>;<volume>91</volume>:1484s-1491s.</citation>
</ref>
</ref-list>
</back>
</article>